---
document_datetime: 2023-09-21 21:25:09
document_pages: 66
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/retsevmo-h-c-005375-ii-0014-g-epar-assessment-report-variation_en.pdf
document_name: retsevmo-h-c-005375-ii-0014-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 109.0335452
conversion_datetime: 2025-12-22 12:12:00.565192
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
21 July 2022 EMA/681951/2022

Committee for Medicinal Products for Human Use (CHMP)

## CHMP group of variations including an extension of indication assessment report

Invented name: Retsevmo

International non-proprietary name: selpercatinib

Procedure No. EMEA/H/C/005375/II/0014/G

Marketing authorisation holder (MAH) Eli Lilly Nederland B.V.

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................6                                  |                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6      |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product..............................................................................................9     |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......10                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................10                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Introduction....................................................................................................11   |                                                                                                         |
| 2.2.2. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                             |
| 2.2.3. Discussion and conclusion on non-clinical aspects................................................14                  |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................14    |
| 2.3.1. Introduction....................................................................................................14   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................14      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................16         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................16      |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................16             |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology                                                                                 | .................................................................16                                     |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................16    |
| 2.4.1. Dose response study........................................................................................16        |                                                                                                         |
| 2.4.2. Main study......................................................................................................17   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy                                                                                      | ............................................................................43                          |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................47          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................47  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................54                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................55                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................56 |
| 2.6. Risk management plan........................................................................................56         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................58                              |
| 2.7.1. User consultation.............................................................................................58     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................58                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................58           |
| 3.1.1. Disease or condition.........................................................................................58      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................58                  |                                                                                                         |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................59             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................59        |
| 3.3. Uncertainties and limitations about favourable effects                                                                 | .............................................60                                                         |
| 3.4. Unfavourable effects...........................................................................................60      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................61                                                             |
| 3.6. Benefit-risk assessment and discussion.................................................................62              |                                                                                                         |
| 3.6.1. Importance of favourable and unfavourable effects                                                                    | ..............................................62                                                        |

<div style=\"page-break-after: always\"></div>

| 3.6.2. Balance of benefits and risks.............................................................................62        |
|----------------------------------------------------------------------------------------------------------------------------|
| 3.6.3. Additional considerations on the benefit-risk balance ...........................................62                 |
| 3.7. Conclusions .......................................................................................................63 |
| 4. Recommendations.................................................................................63                      |
| 5. EPAR changes........................................................................................64                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

adverse event

AESI

adverse events of special interest

ADR adverse drug reaction

ALT alanine aminotransferase

AST aspartate aminotransferase

AUC24

area under the concentration versus time curve, from time 24 hours

BID

twice daily

Cab cabozantinib

CBR clinical benefit rate

CHMP Committee for Medicinal Products for Human Use

CI confidence interval

Cmax

maximum observed drug concentration

CR complete response

CSR clinical study report

DOR duration of response

ECG electrocardiogram

IRC independent review committee

MAA marketing authorisation application

MTC medullary thyroid cancer

MKIs

multikinase inhibitors

NMD non-measurable disease

NSCLC

non-small cell lung cancer

ORR

objective response rate

OS overall survival

PD Progressive disease

PFS progression-free survival

PR

partial response

PT

preferred term

QD Once daily

QTc corrected QT interval

RECIST Response Evaluation Criteria in Solid Tumors

RET REarranged during Transfection

<div style=\"page-break-after: always\"></div>

SAE serious adverse event SmPC Summary of Product Characteristics SMQ standardised MedDRA query TEAE treatment-emergent adverse event TLS tumour lysis syndrome Trt treatment ULN upper limit of normal Van vandetanib

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Eli Lilly Nederland B.V. submitted to the European Medicines Agency on 1 April 2022 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.z                  | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                 | Type IB | None               |
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include first-line treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents 12 years and older based on interim results from Study LIBRETTO-001 (LOXO-RET-17001) on the clinical safety and efficacy of selpercatinib in patients with RET-mutant MTC who are cabozantinib and vandetanib treatment-naïve (MTC:-Cab/-Van). LIBRETTO001 is a global, multicohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours.  As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflelt is updated in accordance.  Version 2.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection. The application also includes an updated Phase II Environmental Risk Assessment in order to reflect the patient population as per the approved indication.

The group of variations requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0398/2021on the granting of a (product-specific) waiver and on the granting of a class waiver.

At the time of submission of the application, the P/0398/2021was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC)

<div style=\"page-break-after: always\"></div>

726/2004 - one year of market protection for a new indication.

## Scientific advice

The Applicant received Protocol Assistance on the development relevant for the approved indication from the CHMP, on 25 July 2019 (EMEA/H/SA/4170/1/2019/PA/III). The advice pertained to the following clinical aspects of the dossier:

- The design of a Phase 1/2 study LOXO-RET-17001, and particularly:
- o Regarding the RET-mutant MTC cohort, the adequacy of the proposed population, and the inclusion of a TKi-naïve subgroup to support a benefit/risk assessment in independent of line of therapy.
- o The adequacy of the proposed datasets to support a benefit/risk assessment in RET-mutant MTC.
- The design of a proposed randomized, open-label, Phase 3 study J2G-MC-JZJB in TKi-naïve patients with locally advanced or metastatic MTC, in particular the proposed patient population, the choice of comparator, the primary endpoint, the possible crossover to the active treatment arm, the statistical plan, and the approach to collection of patient-reported outcomes.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

N/A

| Timetable                                                                                                                                               | Actual dates   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Submission date                                                                                                                                         | 1 April 2022   |
| Start of procedure:                                                                                                                                     | 23 April 2022  |
| CHMP Rapporteur Assessment Report                                                                                                                       | 23 June 2022   |
| PRAC Rapporteur Assessment Report                                                                                                                       | 24 June 2022   |
| PRAC members comments                                                                                                                                   | 29 June 2022   |
| Updated PRAC Rapporteur Assessment Report                                                                                                               | n/a            |
| PRAC Outcome                                                                                                                                            | 07 July 2022   |
| CHMP members comments                                                                                                                                   | 11 July 2022   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                                                                    | 14 July 2022   |
| Opinion                                                                                                                                                 | 21 July 2022   |
| The CHMP adopted a report on similarity of Cometriq with name of the authorised orphan medicinal product(s) on date (Appendix 1)                        | 21 July 2022   |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Retsevmo in comparison with existing therapies (Appendix 2) | 21 July 2022   |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The MAH is seeking an extension of indication of selpercatinib for the first line treatment of advanced RET-mutant medullary thyroid cancer (MTC).

Selpercatinib has a conditional approval for previously treated advanced RET mutant MTC (cabozantinib and/or vandetanib).

## Epidemiology and risk factors, screening tools/prevention

Thyroid cancer can be broken down into 4 main types: papillary, follicular, medullary and anaplastic. Of these 4, medullary thyroid cancer (MTC) is a rare subtype representing about 3% to 5% of all thyroid cancers (Accardo et al. 2017). Medullary thyroid cancer is an uncommon malignant tumour arising from the calcitonin- producing parafollicular cells (C cells) of the thyroid. Robust epidemiology data specific to MTC are sparse.

In adults, MTC occurs as a sporadic entity in 70% to 80% of cases and as familial MTC in 25% of cases. In paediatrics, the aetiology is reversed, with most cases familial in nature and the minority of cases being sporadic. RET point mutations, insertions, or deletions are present in most MTCs, including both familial (i.e., multiple endocrine neoplasia [MEN] and other familial MTC syndromes) and sporadic cases (Ji et al. 2015; Heilmann et al. 2016). An estimated 65% to 90% of sporadic MTCs contain RET mutations (Moura et al. 2009; Romei et al. 2018; Larouche et al. 2019).

## Biologic features

RET is a receptor tyrosine kinase critical to development of the enteric nervous system and kidneys. Genetic alterations in RET have been implicated in the pathogenesis of several human cancers including NSCLC,  poorly  differentiated  thyroid  cancers,  and  MTCs.  RET  can  become  oncogenically  activated through two primary mechanisms:

- 1chromosomal  rearrangements,  which  produce  cytoplasmically  localised  oncogenic  hybrid proteins that fuse the RET kinase domain with a partner protein dimerisation domain and lead to ligand-independent constitutive activity,

and

- 2point  mutations,  insertions,  and  deletions  (indels),  which  directly  or  indirectly  activate  the kinase.

RET point mutations, insertions, or deletions are present in most MTCs (Ji et al. 2015; Heilmann et al. 2016).

<div style=\"page-break-after: always\"></div>

## Clinical presentation, diagnosis and stage/prognosis

Although the overall 10-year survival rate for patients with MTC is high (75% to 85%), the clinical course of MTC is highly heterogeneous, varying from indolent tumours that remain unchanged for many years to aggressive cancers associated with high mortality. However, survival decreases with locally invasive and locally advanced disease. Although surgery can be curative for approximately 85% of patients who present with localized disease, recurrence develops in up to 50% of all patients after surgery (Wells et al. 2015). Metastatic MTC is considered incurable and MTC patients with distant metastasis have a 5year survival of 38% after initial diagnosis (American Cancer Society [https://www.cancer.org/cancer/thryoid-cancer/detectiondiagnosisstaging/survival-rates]). Distant metastasis is the main cause of death in MTC patients. Oncogenic RET mutations occur in the majority of MTCs (Ji et al. 2015), including more than 90% of hereditary MTCs and 50% to 60% sporadic MTC (Donis- Keller et al. 1993; Mulligan et al. 1993; Eng et al. 1994; Hofstra et al. 1994; Agrawal et al. 2013; Ji et al. 2015).

## Management

MTC is not sensitive to radioactive iodine and is only curable through surgical resection (Pacini et al. 2012), but recurrent disease occurs in approximately 50% of patients after resection (Wells et al. 2015). Locally recurrent disease is treated with reoperation and/or external beam radiation therapy. However, these treatments are associated with significant morbidity and are often not curative. Metastatic MTC is managed with resection, radiation, or systemic therapies as noted below, but is currently incurable. Children and adolescents with MTC are treated in the same manner as adults, with initial thyroidectomy then re-resection, radiation, or systemic therapy with recurrent disease (Starenki and Park 2015).

There  are  no  RET-specific  inhibitors  licensed  for  the  treatment  of  first-line  RET-mutant  MTC.  The unselective  MKIs  vandetanib  and  cabozantinib  are  approved  for  the  treatment  of  patients  with unresectable locally advanced or metastatic MTCs, in adults and including children over the age of 5 in the case of vandetanib, irrespective of the RET status and irrespective of prior treatment. Cabozantinib and vandetanib have shown tumour response rates in MTC of 28% and 45% and PFS improvements (over placebo) of 7.2 and 11.2 months, respectively; neither drug has demonstrated an OS benefit (Elisei et al. 2013; Wells et al. 2015).

Patients with advanced RET-mutant MTC have a poor prognosis and a significant unmet medical need.

## 2.1.2. About the product

Selpercatinib is an inhibitor of the RET receptor tyrosine kinase (including KIF5B-RET and CCDC6-RET).

RETSEVMO (Selpercatinib) was granted a CMA on 11 Feb 2021 for

1) the treatment of metastatic RET fusion-positive NSCLC in adult patients who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy,

2)  RET  fusion-positive  thyroid  cancer  who  require  systemic  therapy  following  prior  treatment  with sorafenib and/or lenvatinib and

3) RET-mutant MTC in adult and pediatric patients 12 years of age and older who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

The conditional MA was approved based on ORR and DOR observed in the ongoing Phase 1/2 study, LIBRETTO-001.

<div style=\"page-break-after: always\"></div>

The presence of a RET gene fusion (NSCLC and non-medullary thyroid cancer) or mutation (MTC) should be confirmed by a validated test prior to initiation of treatment with Retsevmo.

The recommended dose of Retsevmo based on body weight is:

-Less than 50 kg: 120 mg twice daily.

-50 kg or greater: 160 mg twice daily.

If  a  patient  vomits  or  misses  a  dose,  the  patient  should  be  instructed  to  take  the  next  dose  at  its scheduled time; an additional dose should not be taken.

Treatment should be continued until disease progression or unacceptable toxicity.

On 21 June 2022, an extension of indication of selpercatinib for the first line treatment of metastatic RET fusion-positive NSCLC Not previously treated with a RET inhibitor was granted.

The MAH is seeking an extension of indication of selpercatinib for the first line treatment of advanced RET mutant MTC

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Selpercatinib is currently being investigated in the Phase 1/2 study, LIBRETTO-001 (LOXO-RET17001). It is a multicenter, single-arm, multicohort, open-label, dose-escalation study in patients 12 years or older with advanced solid tumours, including RET fusion-positive solid tumours, RET-mutant MTC, and other tumours with RET activation.

LIBRETTO-001 was initiated in May 2017. The Phase 1 portion of the study has been completed, and the Phase 2 portion is ongoing.

CHMP protocol assistance was sought on the design of LIBRETTO-001 to support an indication in RETmutant MTC, including whether the inclusion of a small number of patients (at least 10) without prior vandetanib/cabozantinib therapy could support an initial MAA for a broader indication including TKinaïve patients. CHMP considered that ORR data from such a small number of patients would likely not be sufficient to establish a benefit-risk in first line patients.

Data at the DCO date of 15 June 2021 are submitted to support the use of selpercatinib for the treatment of RET mutant advanced MTC regardless of line of therapy. The exploratory objectives are not presented at the DCO.

## 2.1.4. General comments on compliance with GCP

The  MAH  stated  that  the  clinical  trial  LOXO-RET-17001  that  support  the  proposed  indication  of selpercatinib was conducted in accordance with Consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS), International Ethical Guidelines for Biomedical Research Involving Human Subjects,  and  the  International  Conference  on  Harmonisation  (ICH)  Good  Clinical  Practices  (GCP) Guideline (E6).

The clinical trial LOXO-RET-17001 (LIBRETTO-001) conducted outside the European Union meets the ethical requirements of Directive 2001/20/EC.

Study  LOXO-RET-17001  was  subject  to  independent  audit  by  regulatory  authorities.  The  audits performed as of 15 June 2021 were:

<div style=\"page-break-after: always\"></div>

| AgencyName                                          | Audit Dates                | Audit Site                                    |
|-----------------------------------------------------|----------------------------|-----------------------------------------------|
| US FDA                                              | 8 Jan 2020 to 14 Jam 2020  | University of Texas MD Anderson Cancer Center |
| US FDA                                              | 27 Jam 2020 to 7 Feb 2020  | The Ohio State University                     |
| US FDA                                              | 30Jam2020 to 10Feb2020     | Massachusetts General Hospital                |
| Phaimaceuticals amd Medical Devices Agency of Japan | 17 May 2021 to 17 May 2021 | Japan Affiliate                               |

Abbreviations: US FDA =United States Food and Drug Administration

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

The specific inhibitory activity of selpercatinib against RET-dependent tumours has been demonstrated in several in vitro and in vivo studies. Single and repeat dose pharmacokinetic studies have characterized the ADME profile in animals. Repeated-dose toxicity studies of up to 3 months duration were conducted in rats and minipigs. Toxicities common to both species and specific to each were observed and reported in the SmPC. The genotoxicity study revealed an equivocal result in the in vivo micronucleus test. The toxicity study program is satisfactory under ICH S9.

## 2.2.2. Ecotoxicity/environmental risk assessment

Selpercatinib is an inhibitor of the RET tyrosine kinase (encoded by the RET proto-oncogene).

It is used to treat some cancers caused by abnormal changes in the RET gene, which have spread and/or which cannot be removed by surgery:

- non-small cell lung cancer, in adults,
- thyroid cancer in adults,
- medullary thyroid cancer, in adults and adolescents from 12 years of age.

The prevalence calculations are admissible and comply with guidance document EMEA/CHMP/4447/00. The predicted environmental concentration PECsw of selpercatinib in surface water is at 0.033 µg/L, therefore higher than the limit value (0.01 µg/L) set by the guide document EMEA/CHMP/4447/00. Additional phase II trials were therefore conducted.

Regarding phase II studies :

Part A: Fate in the environment

The adsorption coefficient Koc was established on 4 soils and 3 sludges from treatment plants (OECD 106). Adsorption is particularly strong on soils (320285 L/kg on average) whereas it is 988 L/kg on average on sludge.

The high adsorption properties of selpercatinib are also noted in the aquatic sediment degradation study (OECD 308) in which selpercatinib rapidly partitioned into the sediment layer with a half-life in water of less than 'one day. The hydrolysis of selpercatinib (OECD 111) shows that the product is not very hydrolysable with a half-life greater than 1 year regardless of the pH. Aerobic transformation in a sludge system is evaluated according to the OECD 314B protocol. Selpercatinib undergoes multiple transformations with a product representing more than 10% of the initial radioactivity. The time of

<div style=\"page-break-after: always\"></div>

disappearance of 50% of the product (DT50) is 3.46 days in the test and, after adjusting the temperatures, it is established at 7.4 days.

The aerobic transformation in an aquatic sedimentary system is evaluated according to the OECD 308 protocol. The time of disappearance of 50% of the product (DT50) is, after temperature adjustment, 257 and 338 days depending on the sediment tested. Consequently, a test on sedimentary organisms (chironomids) was carried out in Phase II Tier B.

## Tier A: Effects on aquatic organisms

A respiration inhibition test on activated sludge was performed according to the OECD 209 protocol. The no observed effect concentration (NOEC) for activated sludge microorganisms is 1000 mg/L. An algae growth inhibition test was performed according to the OECD 201 protocol. The no observed effect concentration (NOEC) for algae is 1700 µg/L. A reproduction test on Daphnia magna daphnia was carried out according to the OECD 211 protocol.

The NOEC for daphnids is 97 µg/L for mortality, reproduction and growth. A test on Pimephales promelas fish was carried out according to the OECD 210 protocol. The NOEC for fish is 160 µg/L. A test on sedimentary organisms (chironomids) was carried out according to the OECD 218 protocol. The NOEC for chironomids is 298 mg/kg. Based on these ecotoxicity test results, the predicted PNEC noeffect concentrations for the different organisms are established. The PEC/PNEC ratios were calculated and are all well below 1. Selpercatinib therefore does not appear to present a risk to aquatic organisms in the environment.

## Tier B

The bioconcentration factor in BCF fish was measured (OECD 305) since the log Kow of selpercatinib is greater than 3 at pH 7 and pH 9. The normalized values of BCF being 98 and 42 L/kg, they are lower than the threshold of 2000 L/kg. Selpercatinib therefore does not meet the criterion for bioaccumulation.

## PBT potential

The OECD 308 sediment transformation test shows that selpercatinib is very persistent in sediments and fulfills the vP criterion. However, it does not meet the vB criterion since the OECD fish bioaccumulation test showed that the BCF bioconcentration factor is below the regulatory classification thresholds. It is neither bioaccumulable (BCF&lt;2000 L/kg), nor very bioaccumulable (BCF&lt;5000 L/kg). Selpercatinib is therefore not classified as vPvB.

## Summary of main study results

| Substance (INN/Invented Name): selpercatinib/Retsevmo   | Substance (INN/Invented Name): selpercatinib/Retsevmo   | Substance (INN/Invented Name): selpercatinib/Retsevmo   | Substance (INN/Invented Name): selpercatinib/Retsevmo   |
|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
| CAS-number (if available):                              | CAS-number (if available):                              | CAS-number (if available):                              | CAS-number (if available):                              |
| PBT screening                                           |                                                         | Result                                                  | Conclusion                                              |
| Bioaccumulation potential- log K ow                     | OECD107                                                 | pH 5 = 1.30 pH 7 = 3.08 pH 9 = 3.45                     | Not B                                                   |
| PBT-assessment                                          | PBT-assessment                                          | PBT-assessment                                          | PBT-assessment                                          |
| Parameter                                               | Result relevant for conclusion                          |                                                         | Conclusion                                              |
| Bioaccumulation                                         | log K ow                                                | pH 5 = 1.30 pH 7 = 3.08 pH 9 = 3.45                     | not B                                                   |
| Bioaccumulation                                         | BCF                                                     | BCFKgL = 98 and 42 L∙kg - 1                             | not B                                                   |
| Persistence                                             | DT50 or ready biodegradability                          | Sediment (two systems): - DT50 water: 1.6, 0.8 d        | vP                                                      |

<div style=\"page-break-after: always\"></div>

|                                                                     |                                                | - DT50 sediment: 336, 418 d - DT50 whole system: 257, 338 d                                                                                                                                       | - DT50 sediment: 336, 418 d - DT50 whole system: 257, 338 d                                                                                                                                       | - DT50 sediment: 336, 418 d - DT50 whole system: 257, 338 d                                                                                                                                       |                                                                           |
|---------------------------------------------------------------------|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Toxicity                                                            | NOEC or CMR                                    | Toxicity to reproduction observed                                                                                                                                                                 | Toxicity to reproduction observed                                                                                                                                                                 | Toxicity to reproduction observed                                                                                                                                                                 | T                                                                         |
| PBT-statement:                                                      | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB                                                                                                                                                    | The compound is not considered as PBT nor vPvB                                                                                                                                                    | The compound is not considered as PBT nor vPvB                                                                                                                                                    | The compound is not considered as PBT nor vPvB                            |
| Phase I                                                             |                                                |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                           |
| Calculation                                                         | Value                                          | Unit                                                                                                                                                                                              | Unit                                                                                                                                                                                              | Unit                                                                                                                                                                                              | Conclusion                                                                |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0,033                                          |  g/L                                                                                                                                                                                             |  g/L                                                                                                                                                                                             |  g/L                                                                                                                                                                                             | > 0.01 threshold (Y)                                                      |
| Other concerns (e.g. chemical class)                                |                                                |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                                                                   | (N)                                                                       |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                                                                                                                                    | Phase II Physical-chemical properties and fate                                                                                                                                                    | Phase II Physical-chemical properties and fate                                                                                                                                                    | Phase II Physical-chemical properties and fate                            |
| Study type                                                          | Test protocol                                  | Results                                                                                                                                                                                           | Results                                                                                                                                                                                           | Results                                                                                                                                                                                           | Remarks                                                                   |
| Adsorption-Desorption                                               | OECD 106 or …                                  | Soil: Koc = 116050 L∙kg -1 (soil 1) Koc = 341959 L∙kg -1 (soil 2) Koc = 582830 L∙kg -1 (soil 3) Koc = 240301 L∙kg -1 (soil 4) Sludge: Koc = 68 3 L∙kg -1 (sludge 1) Koc = 1180 L∙kg -1 (sludge 2) | Soil: Koc = 116050 L∙kg -1 (soil 1) Koc = 341959 L∙kg -1 (soil 2) Koc = 582830 L∙kg -1 (soil 3) Koc = 240301 L∙kg -1 (soil 4) Sludge: Koc = 68 3 L∙kg -1 (sludge 1) Koc = 1180 L∙kg -1 (sludge 2) | Soil: Koc = 116050 L∙kg -1 (soil 1) Koc = 341959 L∙kg -1 (soil 2) Koc = 582830 L∙kg -1 (soil 3) Koc = 240301 L∙kg -1 (soil 4) Sludge: Koc = 68 3 L∙kg -1 (sludge 1) Koc = 1180 L∙kg -1 (sludge 2) | Soil: average Koc used in ERA, 320285 L∙kg -1                             |
| Ready Biodegradability Test                                         | OECD 301                                       |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                           |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308 DT50 at 12°C                          | System 1 at 12°C - DT50, water = 1.6 days - DT50, sediment = 336 days - DT50, whole system = 257 days - shifting to sediment = 97.6%                                                              | System 1 at 12°C - DT50, water = 1.6 days - DT50, sediment = 336 days - DT50, whole system = 257 days - shifting to sediment = 97.6%                                                              | System 1 at 12°C - DT50, water = 1.6 days - DT50, sediment = 336 days - DT50, whole system = 257 days - shifting to sediment = 97.6%                                                              | Two water, sediment systems evaluated. Sediment risk assessment triggered |
| Phase IIa Effect studies                                            |                                                |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                           |
| Study type                                                          | Test protocol                                  | Endpoint                                                                                                                                                                                          | value                                                                                                                                                                                             | Unit                                                                                                                                                                                              | Remarks                                                                   |
| Algae, Growth Inhibition Test/ Species                              | OECD 201                                       | NOEC                                                                                                                                                                                              | 1700 1700                                                                                                                                                                                         | µg/L                                                                                                                                                                                              | Growth rate Yield                                                         |
| Daphnia sp . Reproduction Test                                      | OECD 211                                       | NOEC                                                                                                                                                                                              | 97                                                                                                                                                                                                | µg/L                                                                                                                                                                                              | Production of immobile offspring                                          |
| Fish, Early Life Stage Toxicity Test/ Species                       | OECD 210                                       | NOEC                                                                                                                                                                                              | 160                                                                                                                                                                                               | µg/L                                                                                                                                                                                              | Total length, wet weight, dry weight                                      |
| Activated Sludge, Respiration Inhibition Test                       | OECD 209                                       | NOEC                                                                                                                                                                                              | ≥ 1000 000                                                                                                                                                                                        | µg/L                                                                                                                                                                                              | Total respiration                                                         |
| Phase IIb Studies                                                   |                                                |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                                                                                                                                                   |                                                                           |
| Sediment dwelling organism                                          | OECD 218                                       | NOEC                                                                                                                                                                                              | 1987                                                                                                                                                                                              | mg/ kg                                                                                                                                                                                            | Chironomus riparius                                                       |

<div style=\"page-break-after: always\"></div>

## 2.2.3. Discussion and conclusion on non-clinical aspects

The ERA for Retsevmo (selpercatinib) file is complete and generally well constructed. It does not give rise to any particular comments and the MAH's conclusions are acceptable. Selpercatinib does not appear to pose a risk to aquatic organisms in the environment and is not classified as a PBT or vPvB. The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of selpercatinib.

The MAH is however recommended to amend the calculations and information regarding the study on aerobic transformation in aquatic sediment systems according to OECD 308 as follows:

- i) The MAH should use the SFO kinetic instead of DFOP for the DT50 derivation of total system 1, Brandywine creek.
2. ii) The MAH should correct the study summaries in the ERA and in the study report in terms of the kinetic used to derive the DT50 value for total system 2, Choptank River.
3. iii) The MAH should recalculate the DT50 values for the water compartments using the FOMC kinetic.
4. iv) The MAH should provide a table in the ERA summarising all DT50 values at 20 and 12 °C.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study Number   | Study Title                                                                                                                                                                                             |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| LOXO-RET-17001 | A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer, and Other Tumours with RET Activation (LIBRETTO-001) |

## 2.3.2. Pharmacokinetics

The pharmacokinetic (PK) properties of selpercatinib were sufficiently characterized in the initial MAA.

There are neither new PK data that would change the main PK features of selpercatinib nor special populations. Also, no revision of section 5.2 PK properties of the SmpC is claimed.

The PK data provided in support of this submission include:

- Descriptive,  noncompartmental  methods  of  analysis  of  selpercatinib  PK  data  from  all  MTC patients enrolled in the pivotal study LOXO-RET-17001 (LIBRETTO-001) as of the submission data cut-off date (10 June 2021) and,

<div style=\"page-break-after: always\"></div>

The PK data of MTC patients from the pivotal study LOXO-RET-17001 are presented in the paragraph 'PK in target population'. For DDI data, Please refer to the paragraph 'Pharmacokinetic interactions studies'.

## Pharmacokinetic in target population

PK data from study LOXO-RET-17001 as of the data cutoff of 10 June 2021 were previously reported in the NSCLC CSR (please refer to EMEA/H/C/005375/II/0011). Of the 757 patients with evaluable PK data, 313 were MTC patients.

Table 1 presents the available steady-state exposure (AUC0-24 and Cmax at steady state [C1D8]) of selpercatinib for patients with MTC taking 160 mg selpercatinib BID with (MTC: +Cab/+Van) or without (MTC:-Cab/-Van; naïve patients) a previous treatment by cabozantinib and/or vandetanib. Figure 1 presented the associated box-plots to visualize the PK parameters distribution.

Table 1: Steady-state (C1D8) PK parameters of selpercatinib in patients with MTC

|        | MTC:-Cab/-Van   | MTC:-Cab/-Van     | MTC:+Cab/+Van   | MTC:+Cab/+Van     |
|--------|-----------------|-------------------|-----------------|-------------------|
|        | Cmar (ng/mL)    | AUC0-24 (ug*h/mL) | Cmax (ng/mL)    | AUC0-24 (ng*h/mL) |
| N      | 128             | 127               | 125             | 123               |
| GM     | 2830            | 46700             | 2630            | 45500             |
| GCV%   | 42              | 46                | 64              | 66                |
| 95% CI | 1130,5880       | 18400.117000      | 929,5940        | 16600,106000      |

Abbreviations: AUCo-24 = area under the plasma concentration-time curve from time 0 to 24 hours; CI = confidence interval; Cmax = maximum plasma concentration; GCV% = geometric coefficient of variation %; GM = geometric mean; MTC = medullary thyroid cancer; N = number of samples.

Sources: Data available from 09 May 2017 to 10 June 2021.

Figure 1: Boxplots of plasma selpercatinib Cmax and AUC0-24 following selpercatinib 160 mg BID administrations (C1D8)

<!-- image -->

The steady-state exposure for selpercatinib in MTC: -Cab/-Van patients and MTC: +Cab/+Van patients was comparable. The geometric mean AUC0-24and Cmax PK parameters were similar and the 95%CI overlapped substantially in MTC: -Cab/-Van and MTC: +Cab/+Van patients.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Certain point mutations in RET or chromosomal rearrangements involving in frame fusions of RET with various partners can result in constitutively activated chimeric RET fusion proteins that can act as oncogenic drivers by promoting cell proliferation of tumour cell lines. In in vitro and in vivo tumour models, selpercatinib demonstrated anti-tumour activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6 RET, KIF5B RET, RET V804M, and RET M918T. In addition, selpercatinib showed anti-tumour activity in mice intracranially implanted with a patient-derived RET fusion-positive tumour.

## Primary and secondary pharmacology

No new data have been submitted as part of this application.

## 2.3.4. PK/PD modelling

No new data have been submitted as part of this application.

## 2.3.5. Discussion on clinical pharmacology

In the current submission, PK data in MTC patients from the pivotal study LOXO-RET-17001 (cut-off date of 10 June 2021, N=313) were provided. Using a NCA approach, PK exposure parameters at steadystate (AUC0-24h, Cmax) were determined from MTC patients RET-naïve (max n=128) and RET-prior (max n=125). Overall , steady state systemic exposure of selpercatinib in patients with MTC naïve vs those with prior systemic therapy appears to be similar.

## 2.3.6. Conclusions on clinical pharmacology

Overall, no significant difference in PKs characteristics of selpercatinib is observed in patients with MTC RET-naïve (-Cab/-Van) compared to patients with MTC RET-prior systemic therapy (+Cab/+Van).

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

Study LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours that was initiated in May 2017. The Phase 1 portion of the study allowed to determine the maximum tolerated dose and recommended Phase 2 dose of selpercatinib. A dose of 160 mg BID was selected for Phase 2.

The approved dose as recommended in the SmPC is 160 mg taken orally twice daily (body weight 50 mg or greater).

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

Study LOXO-RET-17001 (LIBRETTO-001): A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET 0Fusion-Positive Solid Tumours, RET-mutant Medullary Thyroid Cancer (MTC), and Other Tumours with RET Activation

## Methods

Figure 2: depicts the study design for the latest protocol version 9.0.

<!-- image -->

## Study participants

Eligibility criteria remained mostly the same as specified in the previous CSR (17 June 2019 data cutoff, see EPAR for Retsevmo initial MA), except for the following listed below, which were updated in version 8.0 or 9.0 of the protocol.

## Inclusion Criteria for Phase 1

- Inclusion Criterion [2] -amended to remove the prohibition of prior treatment with a selective RET inhibitor(s) (including investigational selective RET inhibitor[s]).
- Inclusion Criterion [5] - amended to note the exclusion of minor patients in Canada and Germany.

Phase2

<div style=\"page-break-after: always\"></div>

- Criterion  [11]:  -  allowed  enrolment  of  patients  with  adequate  renal  function,  with  estimated glomerular  filtration  rate  ≥  30  mL/minute  (up  to  6  participants  with  an  eGFR  ≥  15  and  &lt;  30 mL/minute were allowed to enroll with Sponsor approval).
- Criterion [13]: - amended to include additional details on observing conventional and effective birth control for the duration of treatment and for 3 months

## Inclusion Criteria for Phase 2

- Inclusion Criterion [1] -updated standard of care therapy criteria for Cohorts 2 and 4.
- Inclusion Criterion [5] - added to describe the inclusion criteria for Cohort 6: Participants who were otherwise eligible for Cohorts 1 to 5 who discontinued another RET inhibitor due to intolerance could be eligible with prior Sponsor approval.

## Exclusion Criteria for Phase 1 and Phase 2:

- Exclusion Criterion [2] - amended to further describe the inclusion criteria for Cohorts 1 through 6.
- Exclusion Criterion [3] - modified to further describe exclusion criteria for investigational agents or anticancer therapies.
- Exclusion Criterion [8] - modified to revise the criterion for QTcF.
- Exclusion Criterion [9] - amended to exclude patients with serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment.
- Exclusion Criterion [13] -amended to further clarify prohibited concomitant medications.
- Exclusion Criterion [17] - added to exclude patients with a history of hypersensitivity to any of the study intervention capsule components.

## Treatments

The RP2D of selpercatinib (160 mg BID) was selected in Phase 1 and has been used as the starting dose for patients in the Phase 2 dose expansion phase of the study.

Patients continued selpercatinib dosing in 28-day cycles until PD, unacceptable toxicity, or other reason for treatment discontinuation. Patients with PD could continue selpercatinib if, in the opinion of the Investigator, the patient was deriving clinical benefit from continuing study treatment, and continuation of treatment was approved by the Sponsor.

<div style=\"page-break-after: always\"></div>

## Objectives and endpoints

Table 2. Objectives and endpoints of LIBRETTO-001 (Phase 2)

| Objectives (Phase 2)                                                                              | Endpoints (Phase 2)                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                           |                                                                                                                                                                                                                                                             |
| To asscss the antitumor activity of selpercatinib in patients with RET- mutant MTC                | ORR based on IRC asscssment using RECIST 1.1                                                                                                                                                                                                                |
| Secondary                                                                                         |                                                                                                                                                                                                                                                             |
| To assess the antitumor activity of selpercatinib in patients with RET- mutant MTC                | ORR based on Investigator asscssment using RECIST 1.1 TTR, TTBR, DoR, CBR based on IRC and Investigator asscssment PFS bascd on IRC and Invcstigator asscssment OS                                                                                          |
| To determine the safety profile and tolerability of selpercatinib in patients with RE7-mutant MTC | Safety pcr CTCAE (including but not limitcd to): frequency, severity, and relatedness of TEAEs, SAEs, deaths, and clinical laboratory abnormalities Changcs in hacmatology and blood chcmistry valucs Asscssments of physical cxaminations Vital signs ECGs |
| To characterize the PK propertics of selpercatinib                                                | Plasma concentrations of selpercatinib and PK paramcters, including. but not limited to, AUCo-24. Cmax. and Tmax                                                                                                                                            |

Abbreviations: AUCo-24 = area under the plasma concentration-time curve from 0 to 24 hours; CBR = clinical Advcrse Evcnts; DoR = duration of rcsponsc; ECG = clectrocardiogram; IRC =Indcpendent Review Committcc; MTC =medullary thyroid cancer; ORR = overall response rate; OS = overall survival; PFS = progression-frcc survival; PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; RET = REarranged during Transfection; SAE = serious adverse event; TEAE = treatment-emergent adverse event; Tmax = time to maximum plasma concentration; TTBR = time to best response; TTR = time to response.

## Sample size

Under the planned primary analysis of effectiveness, a true ORR of ≥ 40% is hypothesized when LOXO292 is administered to patients with RET-mutant MTC who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options.

A sample size of 55 patients is estimated to provide 89% power to achieve a lower boundary of a 2sided 95% exact binomial confidence interval (CI) about the estimated ORR that exceeds 20%. Ruling out a lower limit of 20% for ORR is considered clinically meaningful patients who have failed prior multikinase inhibitor therapy (eg, cabozantinib and/or vandetanib), are in need of systemic therapy, and have limited treatment options for their advancing disease. Under the primary analysis, the lower limit of the 95% CI will exceed 20% when the estimated ORR is 33% or greater (Clopper-Pearson method).

## Randomisation

The study was not randomised.

## Blinding (masking)

The study was not blinded.

## Statistical methods

Statistical Analysis Plan

<div style=\"page-break-after: always\"></div>

The protocol (appendix [Protocol and Addenda]) and the SAPs approved prior to database lock (appendix [Documentation of Statistical Methods]) provide the planned analyses for the study, comparisons, statistical tests, and determination of sample size.

This interim report provides clarification regarding the derivation of the analysis sets that support evaluation of the MTC data for selpercatinib.

## Analysis Sets

Patients enrolled into the Phase 1 dose escalation as well as the Phase 1 and Phase 2 dose expansion cohorts were grouped to derive the analysis sets.

The goal of the arrangement of these various data sets was to:

-maximize information through the consolidation of data from both Phase 1 and Phase 2 parts of LIBRETTO-001, and

-define groupings based on clinically meaningful distinctions, resulting in similarity of patients within a group, thus, facilitating the interpretation of results.

## Efficacy Analysis Set for RET-Mutant MTC

Patients with RET-mutant MTC who had received at least 1 dose of selpercatinib and achieved at least 6 months of potential follow-up time from the first dose of selpercatinib (or disease progression or death, whichever occurred first), as of 15 June 2021, were considered eligible for efficacy analyses. Response is assessed approximately every 2 months, and 6 months of follow up provides sufficient time for initial responses to be confirmed.

The evaluation of efficacy consists of RET-mutant MTC analysis sets as defined in Table 3.1 (the basis for the initial regulatory submissions) and includes patients enrolled into Phase 2 Cohorts 3, 4, and 5. Cohort 6 includes patients who have received prior treatment with a selective RET inhibitor but discontinued due to intolerance and are therefore not included in the efficacy analysis; these patients were excluded in LIBRETTO-001 until Cohort 6 was introduced in protocol version 8.

The efficacy analysis for RET-mutant MTC primarily focused on 1) patients not previously treated with cabozantinib and vandetanib (primary efficacy analysis set) and 2) patients previously treated with cabozantinib and/or vandetanib (supportive efficacy analysis set). A total of 314 RET-mutant MTC patients were considered part of the efficacy evaluable dataset. Efficacy was further assessed using the supportive efficacy analysis sets described in Table 3.

<div style=\"page-break-after: always\"></div>

Table 3: Description of Efficacy Analysis Sets

<!-- image -->

| Set Name                                                                | Anslysis Set                                                                                   | Analysis Set Dexcription                                                                                                                                                                                                   | Number of Patients Per Auabysis Set (TotalMTC Effkary Evalusble Dataset N314)   |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Primary Epicagy dnahsis Set                                             | Primary Epicagy dnahsis Set                                                                    | Primary Epicagy dnahsis Set                                                                                                                                                                                                | Primary Epicagy dnahsis Set                                                     |
| MITC:Cab/-Van Previously labolled an \"Supplwenal Analst Ser ! (AST)\"    | Pationts Not Proviously Treated with Cabozsntinib sndlor Vandatanih                            | Includes RET-mutant MTC patients that havo had no prior thenpy bosides cabozantinib and wndetanib; aud mst thecrieria in foolote a.                                                                                        | N=142 Incldes N115ffiow MTC:TrNane ad N-27 fromMTC:TnOther                      |
| MTC:+Cab/+Van Previously laballed an Tntegrted Syfeg Anabasts Ser(TAS)\" | Patients Previously Treated with Cabozantinib audlor Wandatanib                                | Includas all patient with RET-mnlnt MTC previously bealad with caboznfinib and or wndetanib, and met the criterin in foomotea.                                                                                             | N=151 InclwdesN=55ffrom MTC:Iniial+Caby+Van                                     |
| (s noyoog 4 elgeywe) aes sprpoup bwogly ayuoddng oyo                    | (s noyoog 4 elgeywe) aes sprpoup bwogly ayuoddng oyo                                           | (s noyoog 4 elgeywe) aes sprpoup bwogly ayuoddng oyo                                                                                                                                                                       | (s noyoog 4 elgeywe) aes sprpoup bwogly ayuoddng oyo                            |
| MITC:Initial+Cab/+Van Previouwly labelled an \"Prinory dnahss Ser (PAS)* | The Fist S5 Patiente Emrolled who were Previously Treated with Cabozantinib andlor Vandetanib  | Thissnnlysissetisasnbsetoftho\"Patienl:ProviouslyTreated Includas the finst 55 consecutively eurolled patieut with RET- muhant MTC previously treated with cabozantinib and/or Waudetnib; swd met the criteria in foobotea. | N=55                                                                            |
| MTC:MID Previouslylabolled an \"Supplwenial Analsb Ser 2 (8452)\"         | Patiout wih Nou-Meanwablo                                                                      | Includos pafients with RET-mnthnt MTC proviously teated and vl.1; amd mot criteria I amd 3 in foobuoto a. toalment nsfvopatieuts witout meanwnbladitease byRECisT                                                          | N=21                                                                            |
| MITC:TrINaive                                                           | Pationth Narwe to Any Systemie                                                                 | Thit snslyais cet isa subst of the Patiente Not Previously Treated with Cabozantinib and/or Vandatanib\" amalysis set.                                                                                                      | N=115                                                                           |
| MITC:TrtOther                                                           | Patiout: Nalve to Cabozantinib and Vandotanib But Previously Trealed with Other Systemic Adenq | Thit soslysin wet isa smbset of the *Parientes Not Proviously Treated with Cabozautinib and/or Vandatanib\" awalysis set.                                                                                                   | N=27                                                                            |

Abbreviations: CLIA= Clinical Laboralory Improvement Amendmenlr; MTC = medullary tbyroid cancer, MTC:Cab/-Van = Patieut Not Previously Trealed wilh Cabozantinib and/or Vandatanib; MI C.+Cab/+Van =Pationts Previously Treated with Cabozantinib and or Vaudabanib; MTC:Iniial+Cab/+Van =ThoFinst 55 PatieuhEmrolled who woroProvioushy Troated with Cabozautinib and/orVaudatnib;MfTC:NMD=Patieub with Non-Moawurablo Disease, MiTC:IrtNatre= Patients Natvo to Any Syatomic Therapy: MTC:TrtOther = Pationt Nhive to Cabozntinib sud Vandetanib But dhuring Trnsfection; SAP = statistieal analyis plan, SCE = Summury of Climical Effcacy. Critoria for inclusionr

1. Evidenca of a protocol-defined qulifying and dafinitivo RET mutation prospectively identifed bared on a documonted CLLA-certified (or equivaleat oxUS) moleelar pathology' report.

2.1 Mearwnble diwaw by RECiST vl.1 by Inwestigalor awewsmeut. Patient in tho Pha 1 dow erealation portion of the shudy without meanwnbl direaro Were cousidkred. Refer to the MTC SCE SAP for denilk.

3. Recsived I or more doses of olpareafinih.

The efficacy analysis sets were derived to facilitate the regulatory review of the LIBRETTO-001 data. These analysis sets are distinctive from those specified in the protocol and documented in the SAP. This interim CSR follows the SAP (appendix [Documentation of Statistical Methods]) prepared to document and specify the statistical methods used for analyses to demonstrate the effectiveness and the safety of selpercatinib in patients with RET-mutant MTC.

There were no changes in the planned analyses for the study.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 3: RET-mutant MTC efficacy analysis and overall safety populations based on a data cutoff date of 15 June 2021.

<!-- image -->

Abbreviations: BID = twice daily; MTC = medullary thyroid cancer; MITC:-Cab/-Van = Patients Not Previously Treated with Cabozantinib and/or Vandetanib; MT C:+Cab/+Van =Patients Previously Treated with Cabozantimib and/orVandetanib; MlIC:Imitial+Cab/+Van=The First 55 Patients Emolled who were Previously Treated with Cabozamtinib and/or Vandetamib; MI C:NMD = Patients with Non-Measuurable Disease; MTC:IrtNaire = Patients Naive to Any Systemic Therapy; MTC:IrtOther = Patients Naive to Cabozantinib amd Vandetamib But Previously Treated with Other Systemic Therapy; MTD = maximum tolerated dose; nommeasuuable disease; N = mumber of patients; NMD = nommeasuuable disease; NSCLC = non-small-cell lumg camcer, QD = once daily; RET = REairanged dhuing Transfection.

<div style=\"page-break-after: always\"></div>

Table 4: Summary of Disposition RET-Mutant MTC Efficacy Analysis Population Data Cutoff: 15 June 2021

|                                                                    | Primary Analvsis Set   | Subsets ofPrimary AnalysisSet   | Subsets ofPrimary AnalysisSet   | Supportive Analysis Set   | TotalMICa       |
|--------------------------------------------------------------------|------------------------|---------------------------------|---------------------------------|---------------------------|-----------------|
| n (%)                                                              | MTC:-Cab/-Van N=142    | MTC:IrtNaive N=115              | MTC:TrtOther N=27               | MTC:+Cab/+Van N=151       | N=314           |
| Treatment continuing                                               | 118 (83.1)             | 96 (83.5)                       | 22 (81.5)                       | 86 (57.0)                 | 221 (70.4)      |
| Treatment discontinued                                             | 24 (16.9)              | 19 (16.5)                       | 5 (18.5)                        | 65 (43.0)                 | 93 (29.6)       |
| Progressive disease                                                | 5 (3.5)                | 2(1.7)                          | 3 (11.1)                        | 35 (23.2)                 | 40 (12.7)       |
| Adverse event                                                      | 8 (5.6)                | 7 (6.1)                         | 1 (3.7)                         | 12 (7.9)                  | 21 (6.7)        |
| Intercuurent illness compromising ability to filfil protocol       | 0 (0.0)                | 0 (0.0)                         | 0 (0.0)                         | 1(0.7)                    | 1 (0.3)         |
| requirements Requirement for altemative treatment per investigator | 1 (0.7)                | 1 (0.9)                         | 0 (0.0)                         | 2 (1.3)                   | 4 (1.3)         |
| Withdrawal of consent                                              | 6 (4.2)                | 6 (5.2)                         | 0 (0.0)                         | 3 (2.0)                   | 10 (3.2)        |
| Death Other                                                        | 2 (1.4) 2 (1.4)        | 1 (0.9) 2 (1.7)                 | 1 (3.7) 0 (0.0)                 | 6 (4.0) 6 (4.0)           | 8 (2.5) 9 (2.9) |
| Treatment post- progression                                        | 15 (10.6)              | 10 (8.7)                        | 5 (18.5)                        | 47 (31.1)                 | 62 (19.7)       |
| Study status continuing                                            | 128 (90.1)             | 103 (89.6)                      | 25 (92.6)                       | 99 (65.6)                 | 246 (78.3)      |
| Study status discontinued                                          | 14 (9.9)               | 12 (10.4)                       | 2 (7.4)                         | 52 (34.4)                 | 68 (21.7)       |
| Wihdrawal of consent                                               | 6 (4.2)                | 6 (5.2)                         | 0 (0.0)                         | 9 (6.0)                   | 16 (5.1)        |
| Lost to follow-                                                    | (o0)0                  | (00) 0                          | 0 (0.0)                         | 1 (0.7)                   | 1 (0.3)         |
| up Death                                                           | 8 (5.6)                | 6 (5.2)                         | 2 (7.4)                         | 39 (25.8)                 | 47 (15.0)       |
| Other                                                              | 0(0.0)                 |                                 |                                 | 3 (2.0)                   | 4 (1.3)         |
|                                                                    |                        | 0 (0.0)                         | 0 (0.0)                         |                           |                 |

Abbreviations: MIC = medullary thyroid cancer, MT C:+Cab/+Van = Patients Previously Treated with Cabozantinib and/or Vandetamib; MTC:NMD = Patients with Non-Measuable Disease; MTC:TrtNaive = Patients Naive to Any Systemic Therapy; MTC: TrtOther = Patients Naive to Cabozantinib and Vandetamib But Previously Treated with Oher Systemic Therapy; N  mumber of patients; n = number of patients in specific category: NMD = nommeasuable disease; RET = REanranged duwring Transfection.

The total column is calculated ftom the presented MTC:-Cab/-Van (N=142) plus MITC:+Cab/+Van (N=151) as well as the MTC:NMD (N=21) Analysis Sets.

## Recruitment

This study was conducted at 80 centres that enrolled patients in North America, Asia Pacific, European Union, and the Middle East. The study is ongoing.

Study initiation date: 09 May 2017

Data cutoff date for interim analysis: 15 June 2021

Participants screened: 921

Participants treated with at least 1 dose of selpercatinib: 796

Participants with RET mutant MTC: 319

## Conduct of the study

The protocols located in the previous CSR (15 June 2021 data cutoff) provide information about changes in study conduct implemented up to protocol version 9.0. The protocol located in an appendix to this CSR provides information about changes in study conduct implemented by protocol version 9.0 (03 June 2020).

<div style=\"page-break-after: always\"></div>

Table 5: Summary of major changes, subsequent amendments, and the approval dates of the protocol.

| Version Number and Date                                                                                                                                                                      | Major Changesto the Protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8.0 10 Jume 2019                                                                                                                                                                             | New sections were added to define length of shudy and end of study participant has withdrawn consent, is lost to follow-up, has died, or the sponsor makes a decision to close the shudy. Phase 2 descriptions were updated to increase participant numbers following the selectionof160mgBDastheRp2Dandtoaccountforadditionofanewcohort (Cohort 6). Eligibility criteria were added, removed, or modified (as detailed in protocol Section 3.3.1). Additional details were provided regarding the shudy intervention (protocol Section 3.4.1). Additional Investigator guidance regarding possible AEs and re-escalatious were provided. Tests and evaluations were updated to add tests at additional time points and increase frequency of tests (as descnibed in Section 7 of the protocol [appendix Protocol and addenda). Sample size was updated to reflect updated size for Cohort 1 and Cohort 6. Statistical portions were updated to aligu with other protocol sectious. Clarification that efficacy analyses will be conducted on the Safety Analysis Set umless otherwise specified (as described in protocol Section 3.7). Defimition of life-threatening AEs was updated. Examples of multiple kinase inhibitors and RET activating mutations were updated. |
| 8.1 (Denmark) Major changes from protocol version 7.3 (Demmark) to version 8.1 were:                                                                                                         | 8.1 (Denmark) Major changes from protocol version 7.3 (Demmark) to version 8.1 were:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 10 Jume 2019                                                                                                                                                                                 | Rationale for ewrolling participants youmger than 18 years was provided to indicate that participants younger tham 18 years could be emrolled if approved by local instinutional and coumthy regulatory authorities. All otherrevisions weremade toaligu with version8.0.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 8.2 (Japan) 14 Jume 2019                                                                                                                                                                     | Major changes from protocol version 7.2 (Japan) to version 8.2 were: Study design was updated to add clarification of enrollment in Japan. All other revisions were made to aligu with version 8.0.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 8.3 (Germany) 08 October2019                                                                                                                                                                 | Major changes from protocol version 7.4 (Genmany) to version 8.3 were: Clinical safety and data updates were made to aligu with IB version 5.0. Size of Cohort 1 was increased to up to approximately 200 participants. Cohort 6 was added for participants who discontiuued another RET inhibitor due to The 40 mg capsule and liquid suspension were added; the 10 mg capsule was removed. The ECG schedule was updated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Addendum l to V8.0-8.3 02 Apnil 2020                                                                                                                                                         | The pwpose of this addenduum was to allow temporary flexibility in study visits, assessments, andshudydnugdispensationbecauseof the COVD-19pandemic.Theinfonmationin this addendum supplements Protocol Section 7 and Table 7-1 in Protocol version 8.0, version 8.1, Version 8.2, and version 8.3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 9.0 (Global) 03 Jume 2020                                                                                                                                                                    | Major changes from protocol version 8.3 (Genmamy) to version 9.0 were: Aligued changes added in response to EC/RLA quenies in PA8.1 (Demmark), PA8.3 (Gemany), and PA8 addendum (Canada). Clinical safety and data updates were made to aligu with the IB V7.0. approximately 200. Reduced the requirement for in-climic visits beyond C7 and provided the optious of telemedicine and visits to local healthcare providers dwing nondisease assessment cycles.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Abbreviations:AE=adverse event;BD=twice daily;C=cycle; COVID-19 =coronavinus disease 2019;EC = Ethics Committee;ECG=electmocardiogram;IB=Imvestigator'sBrochwre;LTFU=long-tenm follow-up:RA= | Abbreviations:AE=adverse event;BD=twice daily;C=cycle; COVID-19 =coronavinus disease 2019;EC = Ethics Committee;ECG=electmocardiogram;IB=Imvestigator'sBrochwre;LTFU=long-tenm follow-up:RA=                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

## Protocol Deviations

Important protocol deviations were defined as those which could potentially impact the study assessment, participant rights, and the study integrity. Protocol deviations were reviewed by the Sponsor and none of these deviations were considered to have a marked impact on safety or efficacy evaluations.

Important protocol deviations for this interim analysis were the same as those reported in the previous NSCLC CSR (15 June 2021 data cutoff).

Table 6: Summary of Important Protocol Deviations Data Cutoff: 15 June 2021

| Category                                | NSCLC Safety Population (N=356) n (%)   | Overall Safety Population (N=796) n (%6)   |
|-----------------------------------------|-----------------------------------------|--------------------------------------------|
| Patients with Major Protocol Deviations | 92 (25.8)                               | 161 (20.2)                                 |
| Investigational Product                 | 33 (9.3)                                | 61 (7.7)                                   |
| Study Proceduues                        | 21 (5.9)                                | 43 (5.4)                                   |
| SAE Reporting                           | 18 (5.1)                                | 35 (4.4)                                   |
| Resticted Concomitant Medication Change | 19 (5.3)                                | 23 (2.9)                                   |
| Inclusion Criteria                      | 12 (3.4)                                | 16 (2.0)                                   |
| Withdrawal Criteria                     | 7 (2.0)                                 | 11 (1.4)                                   |
| Exclusion Criteria                      | 3 (0.8)                                 | 5 (0.6)                                    |
| Infonmed Consent                        | 2 (0.6)                                 | 4(0.5)                                     |

Abbreviations: N = mumber of patients; n = mmber of patients in specific category; NSCLC = non-small cell lumg camcer; SAE = serious adverse events.

Source: Table 8.6.

## Baseline data

Demographics

<div style=\"page-break-after: always\"></div>

Table 7: Summary of Demographics RET-Mutant MTC Efficacy Analysis Population Data Cutoff: 15 June 2021

|                                           | Primary Analysis Set   | Subsets of Primary Analysis Set   | Subsets of Primary Analysis Set   | Supportive Analysis Set   | Total MTCa N=314   |
|-------------------------------------------|------------------------|-----------------------------------|-----------------------------------|---------------------------|--------------------|
| Parameter                                 | MIC:-Cab/-Van N=142    | MTC:TrtNaive N=115                | MTC:TrtOther N=27                 | MTC:+Cab/+Van N=151       |                    |
| Age (years, n) Median (Range)             | 57 (15-87)             | 57 (15-87)                        | 58 (21-77)                        | 58.0 (17-90)              | 58 (15-90)         |
| Overall agegroup. n (%)                   |                        |                                   |                                   |                           |                    |
| ≤18 years                                 | 2 (1.4)                | 2(1.7)                            | 0 (0.0)                           | 1 (0.7)                   | 3 (1.0)            |
| 18-44 years                               | 34 (23.9)              | 27 (23.5)                         | 7 (25.9)                          | 29 (19.2)                 | 69 (22.0)          |
| 45-64 years                               | 68 (47.9)              | 54 (47.0)                         | 14 (51.9)                         | 68 (45.0)                 | 145 (46.2)         |
| 65-74 years                               | 23 (16.2)              | 20 (17.4)                         | 3 (11.1)                          | 37 (24.5)                 | 64 (20.4)          |
| 75-84 years                               | 14 (9.9)               | 11 (9.6)                          | 3 (11.1)                          | 14 (9.3)                  | 30 (9.6)           |
| >85 years                                 | 1 (0.7)                | 1 (0.9)                           | 0 (0.0)                           | 2 (1.3)                   | 3 (1.0)            |
| Sex, n (%)                                |                        |                                   |                                   |                           |                    |
| Male                                      | 83 (58.5)              | 71 (61.7)                         | 12 (44.4)                         | 96 (63.6)                 | 190 (60.5)         |
| Female                                    | 59 (41.5)              | 44 (38.3)                         | 15 (55.6)                         | 55 (36.4)                 | 124 (39.5)         |
| Race,n (%)                                |                        |                                   |                                   |                           |                    |
| White                                     | 123 (86.6)             | 99 (86.1)                         | 24 (88.9)                         | 136 (90.1)                | 277 (88.2)         |
| Black or Afican American                  | 2 (1.4)                | 2 (1.7)                           | 0 (0.0)                           | 2 (1.3)                   | 4 (1.3)            |
| Asian                                     | 8 (5.6)                | 6 (5.2)                           | 2 (7.4)                           | 2 (1.3)                   | 13 (4.1)           |
| Native Hawaiian or Other Pacific Islander | 1 (0.7)                | 1 (0.9)                           | 0 (0.0)                           | 0 (0.0)                   | 1 (0.3)            |
| American Indian or Alaska Native          | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 1 (0.7)                   | 1 (0.3)            |
| Other                                     | 7 (4.9)                | 7 (6.1)                           | 0 (0.0)                           | 10 (6.6)                  | 17 (5.4)           |
| Missing                                   | 1 (0.7)                | 0 (0.0)                           | 1 (3.7)                           | 0 (0.0)                   | 1 (0.3)            |
| Ethmicity, n (%)                          |                        |                                   |                                   |                           |                    |
| Hispanic or Latino                        | 7 (4.9)                | 6 (5.2)                           | 1 (3.7)                           | 10 (6.6)                  | 18 (5.7)           |
| Not Hispanic or Latino                    | 132 (93.0)             | 108 (93.9)                        | 24 (88.9)                         | 137 (90.7)                | 289 (92.0)         |
| Missing                                   | 3 (2.1)                | 1 (0.9)                           | 2 (7.4)                           | 4 (2.6)                   | 7 (2.2)            |
| Body weight (kg)                          |                        |                                   |                                   |                           |                    |
| 11                                        | 142                    | 115                               | 27                                | 151                       | 314                |
| Median                                    | 73.2                   | 74.1                              | 65.2                              | 67.6                      | 71.1               |
| Range                                     | 26.8-179.4             | 26.8-148.3                        | 41.9-179.4                        | 36.5-176.8                | 26.8-179.4         |
| Baseline ECOG performance status, n (%)   |                        |                                   |                                   |                           |                    |
| 0                                         | 69 (48.6)              | 53 (46.1)                         | 16 (59.3)                         | 41 (27.2)                 | 120 (38.2)         |
| 1                                         | 67 (47.2)              | 58 (50.4)                         | 9 (33.3)                          | 99 (65.6)                 | 177 (56.4)         |
| 2                                         | 6 (4.2)                | 4(3.5)                            | 2 (7.4)                           | 11 (7.3)                  | 17 (5.4)           |
| Calcitonin (pg/mL)                        |                        |                                   |                                   |                           |                    |
| n                                         | 142                    | 115                               | 27                                | 150                       | 313                |
| Median                                    | 5198.5                 | 3793.0                            | 7548.0                            | 5758.5                    | 5135.0             |
| Range                                     | 51.0-683000.0          | 51.0-151354.0                     | 256.0-683000.0                    | 1.0-200000.0              | 1.0-683000.0       |
| CEA (ng/mL)                               |                        |                                   |                                   |                           |                    |
| n                                         | 141                    | 114                               | 27                                | 150                       | 312                |
| Median                                    | 77.7                   | 66.1                              | 125.7                             | 129.5                     | 92.0               |
| Range                                     | 1.0-14515.0            | 1.0-14515.0                       | 1.8-3069.0                        | 1.7-12412.0               | 1.0-14515.0        |

MTC:-Cab/-Van = Patients Not Previously Treated with Cabozantinib and/or Vandetanib; MTC:+Cab/+Van = Patients Previously Treated with Cabozantinib and/or Vandetanib; MTC:NMD = Patients with Non-Measuable Disease; MTC:IrtNaive = Patients Naive to Any Systemic Therapy: MTC:IrtOther = Patients Naive to Cabozantimib and Vandetamib But Previously Treated with Other Systemic Therapy; N =mumber of patients, n =number of patients in specific category; RET = REaranged dhuring Transfection.

<div style=\"page-break-after: always\"></div>

## Baseline Disease Characteristics

Table 8: Baseline Disease Characteristics - RET-Mutant MTC Efficacy Analysis Population Data Cutoff: 15 June 2021

<!-- image -->

Abbreviations: L = leucine: M = methionine; MTC =medullary thyroid cancer; MTC:-Cab/-Van = Patients Not

Previously Treated with Cabozantinib and/orVandetanib: MTC:+Cab/+Van =PatientsPreviouslyTreated with

MTC:TrtOther =Patients Naive to Cabozantinib and Vandetanib But Previously Treated with Other Systemic

Cabozantinib and or Vandetanib; MT C:TrtNaive = Patients Naive to Any Systemic Therapy:

Therapy: N = mumber of patients; n = mumber of patients in specific category: NGS = next generation sequencing: PCR = polymerase chain reaction; RET = REamanged duing Transfection: T = threonine:

V =valine.

- The total column is caleulated from the presented MTC:-Cab/-Van (N=142) phus MTC:+Cab/+Van (N=151) as well as the MT C:NiliD (N=2l) Analysis Sets.

Sources: Table 8.9. Table 8.10

<div style=\"page-break-after: always\"></div>

## Prior Cancer Therapy

Table 9: Prior Cancer Therapy- RET-Mutant MTC Efficacy Analysis Population Data Cutoff: 15 June 2021

|                                           | Primary Analysis Set   | Subsets of Primary Analysis Set   | Subsets of Primary Analysis Set   | Supportive Analysis Set   | Total MTCa   |
|-------------------------------------------|------------------------|-----------------------------------|-----------------------------------|---------------------------|--------------|
| Parameter                                 | MIC:- Cab/-Van N=142   | MTC:TrtNaive N=115                | MTC:TrtOther N=27                 | MTC:+Cab/+Van N=151       | N=314        |
| Received prior systemic therapy, n (96)   |                        |                                   |                                   |                           |              |
| 5a1                                       | 27 (19.0)              | 0 (0.0)                           | 27 (100.0)                        | 151 (100.0)               | 188 (59.9)   |
| No                                        | 115 (81.0)             | 115 (100.0)                       | 0(0.0)                            | 0 (0.0)                   | 126 (40.1)   |
| Type of prior systemic therapy,b n (96)   |                        |                                   |                                   |                           |              |
| Chemotherapy                              | 5 (3.5)                | 0 (0.0)                           | 5 (18.5)                          | 16 (10.6)                 | 21 (6.7)     |
| Platinum                                  | 4 (2.8)                | 0(0.0)                            | 4 (14.8)                          | 2 (1.3)                   | 6 (1.9)      |
| Taxane                                    | 2 (1.4)                | 0 (0.0)                           | 2 (7.4)                           | 3 (2.0)                   | 5 (1.0)      |
| Immumotherapy                             | 5 (3.5)                | 0 (0.0)                           | 5 (18.5)                          | 13 (8.6)                  | 18 (5.7)     |
| Anti-PD-1/PD-L1 therapy                   | 4 (2.8)                | 0 (0.0)                           | 4 (14.8)                          | 11 (7.3)                  | 15 (4.8)     |
| Anti-CTLA4 therapy                        | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 5 (3.3)                   | 5 (1.6)      |
| Mulikinase inhibitor                      | 10 (7.0)               | 0 (0.0)                           | 10 (37.0)                         | 151 (100.0)               | 170 (54.1)   |
| Cabozantinib                              | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 83 (55.0)                 | 89 (28.3)    |
| Vandetanib                                | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 119 (78.8)                | 123 (39.2)   |
| Sorafenib                                 | 4 (2.8)                | 0(0.0)                            | 4 (14.8)                          | 9(6.0)                    | 13 (4.1)     |
| Leuvatinib                                | 3 (2.1)                | 0(0.0)                            | 3 (11.1)                          | 15 (9.9)                  | 18 (5.7)     |
| Other MKIse                               | 3 (2.1)                | 0(0.0)                            | 3 (11.1)                          | 22 (14.6)                 | 25 (8.0)     |
| Other                                     | 8 (5.6)                | 0(0.0)                            | 8 (29.6)                          | 12 (7.9)                  | 21 (6.7)     |
| Rladioactive Iodine                       | 2 (1.4)                | 0 (0.0)                           | 2 (7.4)                           | 0 (0.0)                   | 3 (1.0)      |
| mTOR inhibitor                            | 1 (0.7)                | 0 (0.0)                           | 1 (3.7)                           | 4 (2.6)                   | 5 (1.0)      |
| VEGFVEGFRinhibitor                        | 0 (0.0)                | 0(0.0)                            | 0 (0.0)                           | 1 (0.7)                   | 1 (0.3)      |
| Honmonal therapy                          | 1 (0.7)                | 0 (0.0)                           | 1 (3.7)                           | 0 (0.0)                   | 1 (0.3)      |
| Other systemic therapyd                   | 4 (2.8)                | 0 (0.0)                           | 4 (14.8)                          | 9 (6.0)                   | 13 (4.1)     |
| Number of prior systemic regimens, n (96) |                        |                                   |                                   |                           |              |
| 0                                         | 115 (81.0)             | 115 (100.0)                       | 0 (0.0)                           | 0(0.0)                    | 126 (40.1)   |
| 1                                         | 22 (15.5)              | 0 (0.0)                           | 22 (81.5)                         | 72 (47.7)                 | 102 (32.5)   |
| 2                                         | 5 (3.5)                | 0 (0.0)                           | 5 (18.5)                          | 37 (24.5)                 | 43 (13.7)    |
| 23                                        | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 42 (27.8)                 | 43 (13.7)    |
| Number of prior systemic                  |                        |                                   |                                   |                           |              |
| regimens                                  |                        |                                   |                                   |                           |              |
| Median                                    | 0.0                    | 0.0                               | 1.0                               | 2.0                       | 1.0          |
| Ramge                                     | 0-2                    | 0-0                               | 1-2                               | 1-8                       | 8-0          |
| Best response tolast systemic             |                        |                                   |                                   |                           |              |
| treatment, n (96)                         |                        |                                   |                                   |                           |              |
| Complete response                         | 0 (0.0)                | 0 (0.0)                           | 0 (0.0)                           | 0 (0.0)                   | 0 (0.0)      |
| Partial response                          | 6 (4.2)                | 0(0.0)                            | 6 (22.2)                          | 15 (9.9)                  | 22 (7.0)     |
| Stable disease                            | 7 (4.9)                | 0 (0.0)                           | 7 (25.9)                          | 55 (36.4)                 | 67 (21.3)    |
| Progressive disease                       | 6 (4.2)                | 0(0.0)                            | 6 (22.2)                          | 36 (23.8)                 | 42 (13.4)    |
| Not evaluated                             | 8 (5.6)                | 0 (0.0)                           | 8 (29.6)                          | 45 (29.8)                 | 57 (18.2)    |
| Prior radiotherapy, n (96)                |                        |                                   |                                   |                           |              |
|                                           | 46 (32.4)              | 35 (30.4)                         | 11 (40.7)                         | 83 (55.0)                 | 138 (43.9)   |
| No                                        | 96 (67.0)              | 80 (69.0)                         | 16 (59.3)                         | 68 (45.0)                 | 176 (56.1)   |
| Prior cancer related surgery, n           |                        |                                   |                                   |                           |              |
| (96)                                      |                        |                                   |                                   |                           |              |
|                                           | 119 (83.8)             | 97 (84.3)                         | 22 (81.5)                         | 136 (90.1)                | 273 (86.9)   |
| No                                        | 23 (162)               | 18 (15.7)                         | 5 (18.5)                          | 15 (9.9)                  | 41 (13.1)    |

<div style=\"page-break-after: always\"></div>

## Exposure

Table 10: Selpercatinib Dose Intensity MTC Safety Population and Overall Safety Population Data Cutoff: 15 June 2021

|                                            | MIC Safety Population N=319   | Overall Safety Population N=796   |
|--------------------------------------------|-------------------------------|-----------------------------------|
| Time on Treatment (months)                 |                               |                                   |
| Median                                     | 24.4                          | 21.3                              |
| Minimum                                    | 0.2                           | 0.1                               |
| Maximm                                     | 47.8                          | 49.0                              |
| Relative Dose Intensity (96)               |                               |                                   |
| Mean (stamdard deviation)                  | 84.5 (19.2)                   | 84.8 (19.1)                       |
| Median                                     | 95.0                          | 94.5                              |
| Range                                      | 17.3-100.1                    | 17.3-100.1                        |
| Relative Dose Intensity Categories, n (%6) |                               |                                   |
| %%06-                                      | 188 (58.9)                    | 468 (58.8)                        |
| 75 to -90%                                 | 44 (13.8)                     | 121 (15.2)                        |
| 50 to ≤75%                                 | 64 (20.1)                     | 145 (18.2)                        |
| -50%                                       | 23 (7.2)                      | 62 (7.8)                          |

## Dose Modifications

Table 11: Dose Modifications in MTC Safety Population and Overall Safety Populations-Data Cutoff: 15 June 2021

|                           | MTC Safety Population N=319   | Overall Safety Population N=796   |
|---------------------------|-------------------------------|-----------------------------------|
| Dose reduction, n (96)    |                               |                                   |
| Any                       | 124 (38.9)                    | 343 (43.1)                        |
| For AE                    | 116 (36.4)                    | 325 (40.8)                        |
| For other reason          | 21 (6.6)                      | 47 (5.9)                          |
| Dose withheld, n (%6)     |                               |                                   |
| Amy                       | 228 (71.5)                    | 580 (72.9)                        |
| For AE                    | 200 (62.7)                    | 510 (64.1)                        |
| For other reason          | 96 (30.1)                     | 229 (28.8)                        |
| Dose imcrease, n (96)     |                               |                                   |
| Any                       | 61 (19.1)                     | 182 (22.9)                        |
| Imtra-patient escalation? | 22 (6.9)                      | 69 (8.7)                          |
| Re-escalationb            | 26 (8.2)                      | 84 (10.6)                         |
| Other reason              | 22 (6.9)                      | 51 (6.4)                          |

Started at a lower dose dhming dose escalation that was subsequently increased

Abbreviations: AE = adverse event; MTC = medullary thyroid camcer; N =muumber of patients; n = muumber of patients in specific category.

b Re-escalation after al dose: reduction.

Souuce: Table 8.16

## Numbers analysed

At the DCO date, 314 patients with RET mutant MTC are included in the efficacy analysis as they had achieved at least 6 months of potential follow-up time from the first dose.

The primary efficacy analysis set to support the proposed first-line indication included 142 patients not previously treated with Cabozantinib and/or Vandetanib (MTC:-Cab/-Van patients); of these 115 patients were naïve to any systemic therapy (MTC:TrtNaive Patients);and 27 patients were naïve to Cabozantinib and Vandetanib but previously treated with other systemic therapy (MTC:TrtOther).

The main supportive analysis sets include:

<div style=\"page-break-after: always\"></div>

o Patients previously treated with Cabozantinib and/or Vandetanib (N=151);

Patients in Cohort 6 (only 1 patient at the DCO), which was introduced in protocol version 8, are not included in the evaluation of efficacy as it is a different population of patients who have received prior treatment with a selective RET inhibitor.

## Outcomes and estimation

## Cabozantinib and/or Vandetanib naïve mutant MTC: -Cab/-Van patients.

Objective Response Rate, Best Overall Response, Duration of Response and Clinical Benefit Rate

Table 12: Response Results RET-Mutant MTC Primary Efficacy Analysis Set (Data Cutoff Date: 15 June 2021)

|                                                              | MITC:-Cab/-Van N=142   | MITC:-Cab/-Van N=142    |
|--------------------------------------------------------------|------------------------|-------------------------|
|                                                              | IRC Assessuent         | Investigator Assessment |
| OverallRlesponseRatea                                        |                        |                         |
| n (96)                                                       | 115 (81.0)             | 110 (77.5)              |
| 95%6 CIb                                                     | 73.6, 87.1             | 69.7, 84.0              |
| Best Overall Response, n (9o)                                |                        |                         |
| Complete response (CR)                                       | 22 (15.5)              | 6 (4.2)                 |
| Partial response (PR)                                        | 93 (65.5)              | 104 (73.2)              |
| Partial response, umconfimmed (uPR)                          | 0 (0.0)                | 1 (0.7)                 |
| Stable disease (SD)                                          | 22 (15.5)              | 27 (19.0)               |
| SD16+G                                                       | 19 (3.4)               | 25 (17.6)               |
| Progressive disease (PD)                                     | 2 (1.4)                | 1 (0.7)                 |
| Not evaluable                                                | 3 (2.1)                | 3 (2.1)                 |
| Clinical Benefit Rate (CR + PR+ uPR + SD16+c)                |                        |                         |
| m (96)                                                       | 134 (94.4)             | 136 (95.8)              |
| 9596 C1b                                                     | 89.2, 97.5             | 91.0, 98.4              |
| Disease Conirol Rate (CR + PR + uPR. + SD)                   |                        |                         |
| n(96)                                                        | 137 (96.5)             | 138 (97.2)              |
| 9596 CIb                                                     | 92.0,98.8              | 92.9, 99.2              |
| Duration of Response                                         |                        |                         |
| Respouders,                                                  | 115                    | 110                     |
| Mediam in months (95%6 C1)d,e                                | NE (NE, NE)            | NE (NE, NE)             |
| Censored n (96)                                              | 100 (87.0)             | 98 (89.1)               |
| Reason Ceusored n (96)                                       |                        |                         |
| Alive without dociwmented disease progression                | 94 (81.7)              | 91 (82.7)               |
| Discontinmed from shudy without dociumentedPD                | 3 (2.6)                | 3 (2.7)                 |
| Diedor dociumented PDaftermissingtwo ormorecomsecmtivevisits | 0 (0.0)                | 1 (0.9)                 |
| Discontinued teatment and lost to follow- P                  | 3 (2.6)                | 3 (2.7)                 |
| Rate (9o) of Duration of Responsedf                          |                        |                         |
| 12 months (9596 C1)                                          | 91.9 (85.0, 95.7)      | 95.2 (88.9, 98.0)       |
| 24 months (9596 C1)                                          | 83.7 (73.0, 90.4)      | 83.7 (72.1, 90.8)       |
| 36 months (9596 C1)                                          | 76.7 (57.1, 88.2)      | 83.7 (72.1, 90.8)       |
| Duration of Follow, Up (months)eg                            |                        |                         |
| Median                                                       | 20.3                   | 21.2                    |
| 95%6 CI for mediam                                           | 17.7, 22.1             | 17.5, 23.1              |
| 25th, 75th perceutiles                                       | 14.2,25.8              | 13.8, 25.8              |

<div style=\"page-break-after: always\"></div>

Figure 4. Waterfall plot of best change in tumour burden RET-mutant MTC Primary Efficacy Analysis Set (Data cut-off: 15 June 2021)

Time to Response and Time to Best Response

<!-- image -->

Table 13 : Time to Response and Based on IRC and Investigator's Assessments RET -Mutant MTC Primary Efficacy Analysis Set (Data Cutoff Date: 15 June 2021)

|                                                     | MTC:-Cab/-Van N=142   | MTC:-Cab/-Van N=142     |
|-----------------------------------------------------|-----------------------|-------------------------|
|                                                     | IRICAssessment        | Investigator Assessment |
| Patients with Best Rlesponse of Confirmed CR or PR, | 115                   | 110                     |
| Time to Response (months)a                          |                       |                         |
| Mediam                                              | 3.5                   | 3.5                     |
| 25th, 75th Percentiles                              | 1.8, 5.5              | 1.8, 5.4                |
| Minimm, Maximm                                      | 0.7, 19.8             | 0.7, 22.1               |
| Time to Response,  (96)                             |                       |                         |
| 2 months                                            | 51 (44.3)             | 44 (40.0)               |
| ≥2 to 4months                                       | 29 (25.2)             | 33 (30.0)               |
| 24 months                                           | 35 (30.4)             | 33 (30.0)               |
| Time to Best Response (months)b                     |                       |                         |
| Median                                              | 3.6                   | 3.6                     |
| 25th, 75th percentiles                              | 1.8, 7.4              | 1.8,5.6                 |
| Min, max                                            | 0.7,34.0              | 0.7,22.1                |
| Time to Best Response, n (96)                       |                       |                         |
| 2 months                                            | 43 (37.4)             | 42 (38.2)               |
| 22 to 4 months                                      | 24 (20.9)             | 31 (28.2)               |
| 24 months                                           | 48 (41.7)             | 37 (33.6)               |

Abbreviations: CR = complete response; IRC =Independent Review Commitee; max =maximum; min =minimum; MTC =medullary thyroid cancer; MTC:-Cab/-Van = Patients Not Previously Treated with Cabozantinib and/or Vandetamib; N = muumber of patients; n = number of patients in specific category:. PR = partial response; RE T = REamranged during Transfection.

- Time to response is defined as number of months elapsed between the date of the first dose of selpercatinib and the first documentation of overall response (CR or PR. whichever occuuted earlier) that was subsequently confinmed.
- b Time to Best Response is defined as the nwmber of months elapsed between the date of the first dose of selpercatimib and the first documeutation of CR (ifpatient's best response is confinmed CR) or PR (if patient's

Souuces:Table 8.22.Table 8.23

<div style=\"page-break-after: always\"></div>

Progression Free Survival

Table 14: Progression-Free Survival Based on IRC and Investigator Assessment RET-Mutant MTC Primary Efficacy Analysis Set (Data Cutoff Date: 15 June 2021)

|                                                                                                | MTC:-Cab/-Van N=142   | MTC:-Cab/-Van N=142     |
|------------------------------------------------------------------------------------------------|-----------------------|-------------------------|
| Status                                                                                         | IRC Assessment        | Investigator Assessment |
| Progression Status, n (96)                                                                     |                       |                         |
| Disease progression                                                                            | 19 (13.4)             | 17 (12.0)               |
| Died (no disease progression beforehand)                                                       | 5 (3.5)               | 3 (2.1)                 |
| Censored                                                                                       | 118 (83.1)            | 122 (85.9)              |
| Reason Censored, o (96)                                                                        |                       |                         |
| Alive without documented disease progression                                                   | 103 (75.2)            | 106 (74.6)              |
| Subsequent anti-cancer therapy or cancer- related surgery without document progressive disease | 5 (3.5)               | 3 (2.1)                 |
| Discontinued from study without dociumented progressive disease                                | 5 (3.5)               | 6 (4.2)                 |
| Died or documented progressive disease after missing 2 or more consecutive visits              | 1 (0.7)               | 2(1.4)                  |
| Discontinued treatment snd lost to follow-up                                                   | 4 (2.8)               | 5 (3.5)                 |
| Progression-Free Survival (months)a.b                                                          |                       |                         |
| Median                                                                                         | NE                    | NE                      |
| 9596 CI for median                                                                             | NE, NE                | NE, NE                  |
| Min, max                                                                                       | 0.0+,42.2+            | 0.0+, 43.7+             |
| Duration of Follow-Up (months)b,c                                                              |                       |                         |
| Median                                                                                         | 24.5                  | 24.8                    |
| 9596 CI for median                                                                             | 22.0, 25.2            | 22.1, 27.3              |
| 25th, 75th percentiles                                                                         | 17.4,30.2             | 17.2, 30.2              |
| Rate (96) of Progression-Free Survivalad                                                       |                       |                         |
| 12 months (95% CI)                                                                             | 91.0 (84.7, 94.8)     | 93.3 (87.6, 96.5)       |
| 24 months (95%6 C1)                                                                            | 81.1 (72.4, 87.3)     | 84.1 (75.6, 89.8)       |
| 36 months (95%6 CI)                                                                            | 74.4 (59.5, 84.5)     | 79.2 (67.4, 87.1)       |

Figure 5. Kaplan-Meier plot of progression-free survival based on IRC assessments -RET-mutant MTC Efficacy Analysis Set (Data cutoff: 15 June 2021)

<!-- image -->

Abbreviations:IR.C=Independent Review Committee: MTC=medulary thyroid camcer: No.=mumber: +=Censored: PFS = progressiou-free suurvival; RET = REarranged during Transfection. Source: F14.2.4.1

<div style=\"page-break-after: always\"></div>

## Overall Survival

Table 15: Overall Survival RET-Mutant MTC Primary Efficacy Analysis Set (Data Cutoff Date: 15 June 2021)

| Status                            | MITC:-Cab/-Van N=142   |
|-----------------------------------|------------------------|
| Survival Status n (9o)            |                        |
| Died                              | 8 (5.6)                |
| Censored                          | 134 (94.4)             |
| Overall Survival (months)ab       |                        |
| Median                            | NE                     |
| 95%6 CI for median                | NE, NE                 |
| Min, max                          | 1.9+, 44.4+            |
| Duration of Follow-up (months)b.c |                        |
| Median                            | 26.3                   |
| 9596 CI for median                | 24.3, 27.8             |
| 25h, 75th percentiles             | 20.7, 31.2             |
| Rate (96) of Overall Survivala.d  |                        |
| 12 months (9596 C1)               | 99.3 (94.9, 99.9)      |
| 24 mouths (95%6 C1)               | 95.0 (89.0, 97.7)      |
| 36 months (95%6 C1)               | 89.7 (76.2, 95.8)      |

Abbreviations: CI=confidence iuterval; max =maximum; min =mimimmm; MTC:-Cab/-Van =Patients Not

Solaleo pagtoads aqi m sjnedpyed go raqumn = N tqiuelapue/ roypue qpuymezoqeo pim paieai1 Aisnotnaid NE = not estimable; RE'T = REamanged duing Tramsfection.

Estimate based on Kaplan-Meier method.+=Censored observation

b 95%6 CI was caleulated using Brookmeyer and Crowley method.

Estimate based on Rleverse Kaplan-Meier method.

d 95%6 CI was calculated using Greenwood's fonmula.

Note: Status as of the last contact on or before 15 Jime 2o21.

Data cutoff: 15 June 2021.

Source: Table 8.26

## Ancillary analyses

MTC:-Cab/-Van patients

<div style=\"page-break-after: always\"></div>

Figure 6: Forest plot of objective response rate in special/subgroup populations by demographics and baseline characteristics based on IRC assessments in MTC:-Cab/-Van patients- data cutoff: 15 June 2021.

Subjct

<!-- image -->

Abbreviatious: IRC =Independent Review Comumitee; MiTC:-Cab/-Van =Patients Not Previously Treated with Cabozantimib and/or Vandetanib.

<div style=\"page-break-after: always\"></div>

Figure 7: Forest plot of objective response rate in special/subgroup populations by demographics and baseline characteristics based on IRC assessments in MTC:+Cab/+Van patients data cutoff: 15 June 2021.

Hubject

<!-- image -->

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 16. Summary of Efficacy for trial LIBRETTO-001

| Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer and Other Tumours with RET Activation (LIBRETTO-001)   | Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer and Other Tumours with RET Activation (LIBRETTO-001)   | Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer and Other Tumours with RET Activation (LIBRETTO-001)   | Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumours, Including RET Fusion-Positive Solid Tumours, Medullary Thyroid Cancer and Other Tumours with RET Activation (LIBRETTO-001)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                | LOXO-RET-17001; LIBRETTO-001                                                                                                                                                                                    | LOXO-RET-17001; LIBRETTO-001                                                                                                                                                                                    | LOXO-RET-17001; LIBRETTO-001                                                                                                                                                                                    |
| Design                                                                                                                                                                                                          | Phase 1/2, multicentre, open-label                                                                                                                                                                              | Phase 1/2, multicentre, open-label                                                                                                                                                                              | Phase 1/2, multicentre, open-label                                                                                                                                                                              |
| Design                                                                                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                  | ongoing not applicable not applicable                                                                                                                                                                           |
| Hypothesis                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                     |
| Treatments groups                                                                                                                                                                                               | Selpercatinib                                                                                                                                                                                                   | Selpercatinib                                                                                                                                                                                                   | Oral 10-, 20- or 80- mg capsules or 20 mg/mL suspension, QD or BID Dose escalation: 20 mg QD to 240 mg BID. Phase 2: 160mg BID                                                                                  |
| Endpoints and definitions                                                                                                                                                                                       | Primary endpoint                                                                                                                                                                                                | Objective response rate (ORR) by IRC                                                                                                                                                                            | Proportion of patients with best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST, 1.1.                                                                  |

<div style=\"page-break-after: always\"></div>

| Secondary endpoint                                                                        | Duration of Response (DOR) by IRC                                                                                                                                                             | The number of months from the start date of PR or CR, and subsequently confirmed, to the date of disease progression or death.                                                                |
|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Secondary endpoint                                                                        | Progression Free Survival (PFS) by IRC                                                                                                                                                        | The number of months elapsed between the date of the first dose of selpercatinib and the earliest date of documented disease progression or death.                                            |
| Secondary endpoint                                                                        | Overall Survival                                                                                                                                                                              | The number of months elapsed between the date of the first dose of selpercatinib and the date of                                                                                              |
| Not provided, DCO:                                                                        | (OS)                                                                                                                                                                                          | death.                                                                                                                                                                                        |
| 15 June 2021                                                                              | 15 June 2021                                                                                                                                                                                  | 15 June 2021                                                                                                                                                                                  |
| Primary Analysis                                                                          | Primary Analysis                                                                                                                                                                              | Primary Analysis                                                                                                                                                                              |
| RET mutant MTC Cabozantinib/vandetanib treatment naïve DCO: 15 June 2021                  | RET mutant MTC Cabozantinib/vandetanib treatment naïve DCO: 15 June 2021                                                                                                                      | RET mutant MTC Cabozantinib/vandetanib treatment naïve DCO: 15 June 2021                                                                                                                      |
| Treatment group Selpercatinib                                                             | Treatment group Selpercatinib                                                                                                                                                                 | Treatment group Selpercatinib                                                                                                                                                                 |
| Number of subject 142 ORR %by IRC 115 (81)                                                | Number of subject 142 ORR %by IRC 115 (81)                                                                                                                                                    | Number of subject 142 ORR %by IRC 115 (81)                                                                                                                                                    |
| DOR median, months by IRC NE (95% CI) NE,NE PFS median, months by IRC NE                  | DOR median, months by IRC NE (95% CI) NE,NE PFS median, months by IRC NE                                                                                                                      | DOR median, months by IRC NE (95% CI) NE,NE PFS median, months by IRC NE                                                                                                                      |
| Treatment group                                                                           | NE, NE 99.3 (94.9, 99.9) at 12 months 95.0 (89.0, 97.7) at 24 months 89.7 (76.2, 95.8) at 36 months cabozantinib/vandetanib treatment Selpercatinib 151 111 (73.5) (65.7, 80.4) NE (27.2, NE) | NE, NE 99.3 (94.9, 99.9) at 12 months 95.0 (89.0, 97.7) at 24 months 89.7 (76.2, 95.8) at 36 months cabozantinib/vandetanib treatment Selpercatinib 151 111 (73.5) (65.7, 80.4) NE (27.2, NE) |
| Prior                                                                                     | Prior                                                                                                                                                                                         | Prior                                                                                                                                                                                         |
| DCO: 15 June 2021                                                                         | DCO: 15 June 2021                                                                                                                                                                             | DCO: 15 June 2021                                                                                                                                                                             |
| Number of subject ORR %by IRC                                                             | Number of subject ORR %by IRC                                                                                                                                                                 | Number of subject ORR %by IRC                                                                                                                                                                 |
| DOR median,                                                                               | DOR median,                                                                                                                                                                                   | DOR median,                                                                                                                                                                                   |
| 34                                                                                        | 34                                                                                                                                                                                            | 34                                                                                                                                                                                            |
| CI) (25.7, NE)                                                                            | CI) (25.7, NE)                                                                                                                                                                                | CI) (25.7, NE)                                                                                                                                                                                |
| months (95% median, (95% CI)                                                              | months (95% median, (95% CI)                                                                                                                                                                  | months (95% median, (95% CI)                                                                                                                                                                  |
| PFS landmark rates (95% CI) 87.7 (81.2, 92.1) at 12 months 77.2 (69.3, 83.4) at 24 months | PFS landmark rates (95% CI) 87.7 (81.2, 92.1) at 12 months 77.2 (69.3, 83.4) at 24 months                                                                                                     | PFS landmark rates (95% CI) 87.7 (81.2, 92.1) at 12 months 77.2 (69.3, 83.4) at 24 months                                                                                                     |
| 75.0) at 36 months applicable, single arm trial                                           | 75.0) at 36 months applicable, single arm trial                                                                                                                                               | 75.0) at 36 months applicable, single arm trial                                                                                                                                               |
| = confidence interval; NE = not estimable                                                 | = confidence interval; NE = not estimable                                                                                                                                                     | = confidence interval; NE = not estimable                                                                                                                                                     |
| CI                                                                                        | CI                                                                                                                                                                                            | CI                                                                                                                                                                                            |
| 65.5 (53.7,                                                                               | 65.5 (53.7,                                                                                                                                                                                   | 65.5 (53.7,                                                                                                                                                                                   |
| per Not                                                                                   | per Not                                                                                                                                                                                       | per Not                                                                                                                                                                                       |
| (%)                                                                                       | (%)                                                                                                                                                                                           | (%)                                                                                                                                                                                           |
| Effect estimate                                                                           | Effect estimate                                                                                                                                                                               | Effect estimate                                                                                                                                                                               |
| OS                                                                                        | OS                                                                                                                                                                                            | OS                                                                                                                                                                                            |
| months                                                                                    | months                                                                                                                                                                                        | months                                                                                                                                                                                        |

## Clinical studies in special populations

|                                        | Age 65-74 (Older number number)   | subjects /total   | Age 75-84 (Older number number)   | subjects /total   | Age 85+ (Older number number)   | subjects /total   |
|----------------------------------------|-----------------------------------|-------------------|-----------------------------------|-------------------|---------------------------------|-------------------|
| LIBRETTO-001 trial                     | 64/314                            |                   | 30/314                            |                   | 3/314                           |                   |
| Total MTC Efficacy Population, N = 314 |                                   |                   |                                   |                   |                                 |                   |

<div style=\"page-break-after: always\"></div>

## Supportive study

## MTC: +Cab/+Van patients

Table 17: Response Results RET-Mutant MTC Supportive Efficacy Analysis Set

<!-- image -->

|                                                                   | MTC:+Cab/+Van N=151   | MTC:+Cab/+Van N=151     |
|-------------------------------------------------------------------|-----------------------|-------------------------|
|                                                                   | IRC Assessment        | Investigator Assessment |
| Orerall Response Raten                                            |                       |                         |
| n(76)                                                             | 111 (73.5)            | 107 (70.9)              |
| 9596 C1b                                                          | 65.7. 80.4            | 62.9, 78.0              |
| Best Overall Response, n (96)                                     |                       |                         |
| Complete response (CR)                                            | 14(9.3)               | 7 (4.6)                 |
| Pautial response (PR)                                             | 97 (64.2)             | 100 (66.2)              |
| Partial response, wmconfimed (uPR)                                | 0 (0.0)               | 1 (0.7)                 |
| Stable disease (SD)                                               | 31 (20.5)             | 33 (21.9)               |
| SD16+e                                                            | 27 (17.9)             | 28 (18.5)               |
| Progressive disense (PD)                                          | 2 (1.3)               | 5 (3.3)                 |
| Not ewaluable                                                     | 7 (4.6)               | 5 (3.3)                 |
| ClinicalBeuefit Rate (CR +PR+ uPR + SD1o+e)                       |                       |                         |
| n(6)                                                              | 138 (91.4)            | 136 (90.1)              |
| 9596 C1                                                           | 85.7.95.3             | 84.1.94.3               |
| Disease Control Rate (CR + PR + uPR + SD)                         |                       |                         |
| n(6)                                                              | 142 (94.0)            | 141 (93.4)              |
| 95%,CIb                                                           | 89.0, 97.2            | 88.2.96.8               |
| Duration of Response                                              |                       |                         |
| Responders, n                                                     | 111                   | 107                     |
| Median in months (95% C1jde                                       | NE (27.2. NE)         | 31.7 (26.1. NE)         |
| Censored n (76)                                                   | 77 (69.4)             | 69 (64.5)               |
| Reason Censored n (96)                                            |                       |                         |
| Alive without documented disease progression                      | 60 (54.1)             | 62 (57.9)               |
| Subsequent amti-cancer thenpy or cancer related swgery without PD | 8 (7.2)               | 2 (1.9)                 |
| Discontinued from study without documented PD)                    | 5 (4.5)               | 3 (2.8)                 |
| Discontinued treatment and lost to follow-up                      | 4 (3.6)               | 2 (1.9)                 |
| Rate (9b) of Duratiou of Respoused,r                              |                       |                         |
| 12 monihs (95:s CT)                                               | 82.8(74.1, 88.8)      | 80.7 (71.6, 87.1)       |
| 24 months (95%% CD)                                               | 64.5 (52.9, 73.9)     | 61.9 (50.4, 71.5)       |
| 36 months (95%6 C1)                                               | 57.9 (44.0, 69.5)     | 48.7 (33.7. 62.2)       |
| Duration of Follow-Up (months)e!                                  |                       |                         |
| Median                                                            | 22.9                  | 23.0                    |
| 95% CI for median                                                 | 20.3,25.4             | 19.3,26.0               |
| 25th, 75th percentiles                                            | 17.5.29.4             | 15.4.29.2               |

Abbreviations: CI= confidence interval; MTC =medullary thyroid cancer; MT C:+Cab/+Van =Patients Previously Treated with Cabozantinib and/or Vandetanib; N = mumber of patients in population; n = number of patients per category: NE =not ewahuable; ORR = objective response rate; RET =REeamanged during Transfection;

SDl6 =stable disease hsting l6 or more Weeks.

ORR. is defined as the proportion of patients with best overall response of confinwed CR. or PR. Response Was sfep stz nmamssassr ieadar e.q pamnguoo

95% CI was calculated using Clopper-Pearson method.

<div style=\"page-break-after: always\"></div>

Table 18: Response on Last Prior Systemic Therapy Compared to Selpercatinib RET-Mutant MTC Supportive Efficacy Analysis Set

| MTC:+Cab/+Van N = 151         | MTC:+Cab/+Van N = 151                        | MTC:+Cab/+Van N = 151                | MTC:+Cab/+Van N = 151   |
|-------------------------------|----------------------------------------------|--------------------------------------|-------------------------|
|                               | Best response to last systemic therapy D(9b) | Best response to selpercatinib D(96) | p-valuei                |
| Responders                    | 15 (9.9)                                     | 107 (70.9)                           | c0.0001                 |
| Complete Response             | 0 (0.0)                                      | 7 (4.6)                              | c0.0001                 |
| Paurtial Resp onse            | 15 (9.9)                                     | 100 (66.2)                           | c0.0001                 |
| Non-Responders                | 136 (90.1)                                   | 44 (29.1)                            | c0.0001                 |
| Paurtial Response. Unconfiwed | 0 (0.0)                                      | 1 (0.7)                              | c0.0001                 |
| Stuble Disense                | 55 (36.4)                                    | 33 (21.9)                            | c0.0001                 |
| Progressive Disense           | 36 (23.8)                                    | 5 (3.3)                              | c0.0001                 |
| Not Estimated                 | 45 (29.8)                                    | 5 (3.3)                              | c0.0001                 |

McNemar ewact test, assesses the significance of the difference between response rate for the last prior therapy versus responsemte to treatment withselpercatinib.

- Abbreviations: MTC =medullary thyroid cancer: MTC:+Cab/+Van = Patients Previously Treated with Cabozantinib and/or Vandetanib; N= mumber of patients, n =mumber of patients in specific category: RET = REamanged during Transfeclion.

Sowce: Table S.31

Table 19: Response on Last Prior Systemic Therapy Compared to Selpercatinib RET-Mutant MTC Supportive Efficacy Analysis Set

|                                                                       | WTC:+Cab/+Van N= 151   |
|-----------------------------------------------------------------------|------------------------|
| Patienis responding to selpercatinib but mot to prior therapy. n (6)  | 95 (62.9)              |
| Patients responding to both selpercatinib and prior thenpy. n (%6)    | 12 (7.9)               |
| Patients responding to prior therapy but not sepercatinib, n (6)      | 3 (2.0)                |
| Patients who did not respond to selpercatinib or pnior therapy. n i6) | 41 (27.2)              |

Abbreviations: MTC =medullary thyroid cancer, MrTC:+Cab/+Van =Patients Previously Treated with Cabozantinib and'or Vandetanib: N = mumber of patients in the population; n = mumber of patients per category: RET =REamanged duing Transfection.

Souuce: flpnitt\\_mic\\_ias\\_inv.csv

Figure 8. Best change in tumour burden RET-mutant MTC Supportive Efficacy Analysis Set. (Data cutoff: 15 June 2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 20: Time to Response and Time to Best Response Based on IRC and Investigator Assessments RET-Mutant MTC Supportive Efficacy Analysis Set

| Status                                              | MTC:+Cab/+Tan N=151   | MTC:+Cab/+Tan N=151     |
|-----------------------------------------------------|-----------------------|-------------------------|
|                                                     | IRuC Assessment       | Iuwesligator Assessment |
| Palients with Best Respouse of Coufirmed CR. or PR, | 111                   | 107                     |
| Time toRlespouse (mmonths)a                         |                       |                         |
| Mledian                                             | 3.5                   | 3.5                     |
| 25th, 75th Pencemtiles                              | 1.8.5.5               | 1.8. 7.2                |
| Minimmumn, Mawiomum                                 | 0.7.26.6              | 0.7.17.8                |
| Time to Respomse, n (46)                            |                       |                         |
| 2momths                                             | 43 (38.7))            | 46 (43.0)               |
| 22 to 4 months                                      | 32 (28.8)             | 19 (17.8)               |
| 24 months                                           | 36 (23.8)             | 42 (39.2)               |
| Time to Besit Rlespouse (monthsjb                   |                       |                         |
| Mledian.                                            | 3.7                   | 3.7                     |
| 25th, 75th percentiles                              | 1.8, 5.6              | 1.8, 9.0                |
| Mim, max                                            | 0.7.32.9              | 0.7.27.8                |
| Time to Best Rlesponse, u (eb)                      |                       |                         |
| 2momths                                             | 36 (32.4)             | 42 (39.3)               |
| 22 to 4 monihs                                      | 32 (28.8)             | 19 (17.8)               |
| 24 months                                           | 43 (28.5)             | 46.0 (42.9)             |

- Tioe to response is defimed as mumber of monthe elapsed between the date of the first dose of selpercatinib and. the first documentation of ovenll response (CR. or PR. whichever occuwmed earlier) that was subsequently Confinwed.

Abbreviations: CR = complete response: Rrc =Independent Rewiew Commitee: max = mawiowm: mtin=minioum: MTC = oedullsrythyroid cancer: MT C:+Cab/+Van =Patients PrewiousyTreated with Cabozantinib and'or Vandetanib; N = mmber of patients: n = mwmber of patients in specific cate gory: PR. = partial response: RE T = Rleumamged dhuing Tramsfectiom.

- Time to Blest Resp onse is defined as the mwmber of monihs elapsed behween. the daite of the first dlose of selpercatinib amd the first documemtation of C R (if patiemt' s best response is confinmed CRj or PRl (if patient's best response is confimmed PRy that was subsequently comfinmed.

Souuces: Table 8\\_22. Table 8.23

Table 21: Progression-Free Survival Based on IRC and Investigator Assessment RET-Mutant MTC Supportive Efficacy Analysis Set

| Status                                                                                       | MTC:+Cab/+Van N=151   | MTC:+Cab/+Van N=151     |
|----------------------------------------------------------------------------------------------|-----------------------|-------------------------|
|                                                                                              | IRC Assessment        | Tuvestigator Assessment |
| Progression Status, n (9b)                                                                   |                       |                         |
| Disease progression                                                                          | 44 (29.1)             | 60(39.7)                |
| Died (no disease progression beforehand)                                                     | 13 (8.6)              | 6 (4.0)                 |
| Censored                                                                                     | 94 (62.3)             | 85 (56.3)               |
| Reason Censored, o (9b)                                                                      |                       |                         |
| Alive without documented disease progression                                                 | 68 (45.0)             | 72 (47.7)               |
| Subsequent anti-cancer therapy or cancer-related swgery without document progressive disense | 11 (7.3)              | 4 (2.6)                 |
| Discontinued from shudywithout documented progressive disease                                | 11 (7.30              | 7(4.6)                  |
| Discontinued teatment and lost to follow-up                                                  | 4(2.0)                | 2(1.3)                  |
| Progression-Free Survival (months)n.b                                                        |                       |                         |
| Medlian                                                                                      | 34.0                  | 33.4                    |
| 9596 CI for median                                                                           | 25.7. NE              | 24.7, NE                |
| Min, maw                                                                                     | 0.0+.42.2+            | 0.0+,46.0+              |
| Duration of Follow-Up (monthsjb.r                                                            |                       |                         |
| Median                                                                                       | 27.6                  |                         |
| 9596 C1 for median                                                                           | 24.9.29.8             | 25.0.30.3               |
| 25h, 75th percentiles                                                                        | 19.6, 33.2            | 21.9.33.9               |
| Rate (4b) of Progression-Free Survivalnd                                                     |                       |                         |
| 12 oonhs (95%. C1)                                                                           | 78.7 (70.9.84.6)      | 74.6 (66.7. 80.9)       |
| 24 oonths (95%% C1)                                                                          | 64.4(55.4. 72.0)      | 59.0 (50.2. 66.7)       |
| 36 months (95%6 Cl)                                                                          | 48.3(36.5. 59.1)      | 47.4 (36.9. 57.2)       |

Abbreviations: CI = confidence interval; IR.C =Independent Review Commitee: max =maximum;

mlin = minimuw: MTC = medullary thyroid cancer; MTC:+Cab/+Van = Patients Previously Treated with Cabozantinib andlor Vandetanib: N = mumber of patients: n = mumber of patiemts in specific category: NE = not estimable; RET =REamamged chuingTrmamsfection

Estimnte based on Kaplan-Meier method.+ = Censored observation.

g5y. CI was calculated using Brookmeyer and Crowley method.

Estimntebnsed onReverseKaplan-Meiermethod.

山 95% CI was calculated using Greenwood's fonmla.

Note: Efficacy eligible subjects are defined as the subjects whose first dose date is on or before 24 March 2021. Data cutoff: 15 Jume 2021.

Sowwrces: Table 8.24, Table 8.25

<div style=\"page-break-after: always\"></div>

Figure 9. Kaplan Meier for progression-free survival based on IRC assessments RET-mutant MTC Supportive Efficacy Analysis Set.

<!-- image -->

Table 22: Overall Survival RET-Mutant MTC Supportive Efficacy Analysis Set

| Status                           | MTC:+Cab/+Van N=151   |
|----------------------------------|-----------------------|
| Survival Status n (40)           |                       |
| Died                             | 39 (25.8)             |
| Censored                         | 112 (74.2)            |
| Owerall Suniwal (months)ab       |                       |
| Median                           | NE                    |
| 95%% CI for median               | NE.NE                 |
| Min, max                         | 0.4+.47.8+            |
| Duration of Follow-up (months)be |                       |
| Median                           | 28.8                  |
| 95%% CI for median               | 26.9.30.5             |
| 25th, 75th percentiles           | 22.8, 34.5            |
| Rate (4b) of Overall Suniralnd   |                       |
| 12 months (95% C1)               | 87.7 (81.2.92.1)      |
| 24 m1onths (95% C1)              | 77.2 (69.3. 83.4)     |
| 36 months (95%, CT)              | 65.5 (53.7. 75.0)     |

Abbreviations: CI = confidence interval: max =mawiumum; min =minimuwn; MTC =medullhury thyroid cancer. MlT C:+Cab/+Van = Patients Prewiously Treated with Cabozamtinib and/or Vamdetanib: N =mumber of participants in the specified category: n = mmber of patients in specific category: NE = not estimable: RET = REamanged dhuing Tramsfection.

- Estinnnte based on Kaplan, Meier method.+ =Censored observmtion
- g5y. CI was calculated using Brookmeyer and Crowley method.
- Estimnte based on Reverse Kaplan-Meier method.
- g5l. CI wns calculated using Greenmood's fommulh

Note: Sthtus as of the lhst contact on or before: 15 Jume 2021.

Dala culoff: 15 Jume 2021.

Sowwce: Table 8.26

<div style=\"page-break-after: always\"></div>

## Biochemical Response Rates for Calcitonin and CEA

Table 23: Biochemical Response Rate for Calcitonin and CEA RET-Mutant MTC Supportive Efficacy Analysis Set

<!-- image -->

| Parameter                                         | MTC:+Cab/+Van N=151   | MTC:+Cab/+Van N=151   |
|---------------------------------------------------|-----------------------|-----------------------|
|                                                   | Calcitonin            | CEA.                  |
| Number of Biochemical Respouse Eligible Patieuisa |                       |                       |
| n                                                 | 148                   | 146                   |
| Best Biochemical Respouse (u, 9o)b                |                       |                       |
| Complete response (CR)                            | 41 (27.7)             | 22 (15.1)             |
| Partial response (PR)                             | 95 (64.2)             | 86 (58.9)             |
| Sthble disease (SD)                               | 1 (0.7)               | 23 (15.8)             |
| Progressive disease (PD)                          | 2 (1.4)               | 8 (5.5)               |
| Not ewalumble (NE)                                | 9 (6.1)               | 7 (4.8)               |
| Not detemminede                                   | 0 (0.0)               | 0 (0.0)               |
| Biochemical Respouse Rate (CR + PRJd              |                       |                       |
| n(96)                                             | 136 (91.9)            | 108 (74.0)            |
| 95%6 C1                                           | 86.3.95.7             | 66.1. 80.9            |
| TimetoBiochemical Respouse (months)je             |                       |                       |
| Median                                            | 0.5                   | 1.0                   |
| 25th, 75th percemrile                             | 0.5,0.6               | 0.9.3.6               |
| Minimwm, maxinum                                  | 0.4.6.2               | 0.4.41.4              |
| Time to Best Biochemical Respouse (months)r       |                       |                       |
| Median                                            | 0.5                   | 1.8                   |
| 25th, 75th percemtile                             | 0.5.1.0               | 0.9.3.7               |
| Minimww, mawimum                                  | 0.4,16.5              | 0.5, 41.1             |

<div style=\"page-break-after: always\"></div>

Other Supportive Efficacy Analysis Sets

| Analysis            | Efficacy Output                                                                                                | Locatiou of Full Auaysis   |
|---------------------|----------------------------------------------------------------------------------------------------------------|----------------------------|
| MTC:Toiial+Cab/+Van |                                                                                                                |                            |
| ORR by IR.C         | 70.996 (9596 CI: 57.1.82.4)                                                                                    | Table 8.18                 |
| Rate of DoR. by R.C | 12 m0s: 86.3%6 (9596 CI: 70.2. 94.1) 2400s: 70.9%6(95%6 CI: 52.5.83.3) 36 m0s: 63.2 (9516 CI: 43.7. 77.5)      | Table 8.20                 |
| TTR by RC           | mTTR: 3.7 mos                                                                                                  | Table 8.22                 |
| Rate of PFS by IRC  | 12 m0s: 82.3% (9596 CI: 68.7. 90.4) 24 m10s: 69.8 (9596 C1-55.0, 80.0) 36 m0s: 54.6 (95%6 CI: 38.7, 68.0)      | Table 8.24                 |
| Rhte of os          | 12 m0s: 86.9%6 (95%6 CI: 74.4. 93.5) 24 m0s: 77.1%6 (9596 CI: 63.2. 86.3) 36 005: 69.496 (95%6 C1: 54.0. 80.6) | Table 8.26                 |
| MTC:NMD             |                                                                                                                |                            |
| ORR.by IR.C         | 38.1%. (95%% CI: 18.1. 61.6) 12 m0s: 100.0%. (95%. CI: NE. NE)                                                 | Table 8.18                 |
| Rate of DoR by R.C  | 24m0s: NE (95%. CI: NE.NE) 36 m10s: NE (95%. CI: NE.NE)                                                        | Table 8.20                 |
| TTR by IRIC         | mTTR: 2.7 m0s                                                                                                  | Table 8.22                 |
| Rate of PFS by IR.C | 12 m0s: 95.096 (95%6 CI: 69.5.99.3) 24 m05: 95.0%6 (95%6 CI: 69.5. 99.3) 36 m10s: NE (951. CI: NE. NE)         | Table 8.24                 |
| Rate of os          | 12 m0s: 100.0% (95% CI: NE, NE) 24 m10s: 100.0% (95% CI: NE. NE) 36 m10s: NE (95% CI: NE. NE)                  | Table 8.26                 |
| MTC:TriNaie         |                                                                                                                |                            |
| ORR by IR.C         | 83.596 (95%. C1: 75.4. 89.7) 12 m0s: 91.496 (95%6 C1: 83.5. 95.6)                                              | Table 8.18                 |
| Rate of DoR. by R.C | 2400s: 84.596(95%6 C1: 72.5.91.0) 36 00s: 75.196 (95%6 CI: 49.7. 88.9)                                         | Table 8.20                 |
| TTRL by IRIC        | mTTR: 2.7 m0s                                                                                                  | Table 8.22                 |
| Rate of PFS by IR.C | 12 m0s: 89.9%6 (95%6 CI: 84.2. 94.2) 24 m0s: 81.6%6 (95% CI: 71.6, 88.4) 36 m0s: 73.4%6 (9596 CI: 52.2. 86.4)  | Table 8.24                 |
| Rateof os           | 12 00s: 99.1% (9596 C1: 93.7. 99.9) 24 m0s: 94.796 (9596 C1: 87.5, 97.8) 36 005: 88.8% (95% C1: 69.0. 96.3)    | Table 8.26                 |
| MITC:Trtotber       |                                                                                                                |                            |

ORR. by RC

70.4%6 (959.CI: 49.8.86.2)

Table 8.18

<div style=\"page-break-after: always\"></div>

| Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Efficacy Ouiput                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Location of Full Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rate of DoR by R.C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12 m105: 94.4%6 (9596 C1: 66.6, 99.2) 24 m0s: 77.5%6 (95%. CI: 43.6.92.5) 36 mos: NE (NE, NE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Table 8.20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| TTR. by IR.C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | mTTR:5.5m0s                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Table 8.22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Rate of PFS by IR.C                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12 m10s: 96.296 (9596 C1: 75.7. 99.4) 24 m0s: 78.296 (95%6 CI: 54.9, 90.4) 36 m0s: 72.296 (95%. C1: 47.5. 86.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Table 8.24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Rate of os                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12 m0s: 100.0% (95% CI: NE. NE) 24 m0s: 96.0%6 (95%6 CI: 74.8, 99.4) 36 005: 90.096 (9596 C1: 64.6. 97.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Table 8.26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| By-patient listing of efficacy outcomes based on INV assessments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Individual Emicacy Response Data appendix                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| By-patient listing of efficacy outcomes based on IRiC assessments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Individual Efficacy ResponseDaa appendix                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Abbreviations: CI =confidence interval: DoR: dwation of response:INV =investigator:IRC =Imdependent Review Committee: mos =months: MfTC:InitialCab/+Van = The First 55 Patients Emrolled who were Previously Treated with Cabozantinib and'or Vandetanib: M IC:NMD = Patients with Non-Measuable Disease. MTC:TriNaire =Patients Naive to Any Systemic Therapy: MTC:TrtOther =Patients Naive to Cabozantinib and Vandetamib But Previously Treated with Other Systemic Therapy. mTTR. =modified time-to-response: NE = not evaluable; PFS = progression-fee suwrvival; ORR = objective response rate; OS = overall swvival: TTR=time-to-response. | Abbreviations: CI =confidence interval: DoR: dwation of response:INV =investigator:IRC =Imdependent Review Committee: mos =months: MfTC:InitialCab/+Van = The First 55 Patients Emrolled who were Previously Treated with Cabozantinib and'or Vandetanib: M IC:NMD = Patients with Non-Measuable Disease. MTC:TriNaire =Patients Naive to Any Systemic Therapy: MTC:TrtOther =Patients Naive to Cabozantinib and Vandetamib But Previously Treated with Other Systemic Therapy. mTTR. =modified time-to-response: NE = not evaluable; PFS = progression-fee suwrvival; ORR = objective response rate; OS = overall swvival: TTR=time-to-response. | Abbreviations: CI =confidence interval: DoR: dwation of response:INV =investigator:IRC =Imdependent Review Committee: mos =months: MfTC:InitialCab/+Van = The First 55 Patients Emrolled who were Previously Treated with Cabozantinib and'or Vandetanib: M IC:NMD = Patients with Non-Measuable Disease. MTC:TriNaire =Patients Naive to Any Systemic Therapy: MTC:TrtOther =Patients Naive to Cabozantinib and Vandetamib But Previously Treated with Other Systemic Therapy. mTTR. =modified time-to-response: NE = not evaluable; PFS = progression-fee suwrvival; ORR = objective response rate; OS = overall swvival: TTR=time-to-response. |

Note: Median DoR not displyed in table because it was not reached for all analysis sets. See Table 8.20.

## 2.4.3. Discussion on clinical efficacy

The p rovided efficacy data in support of the currently intended indication 'treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) not previously treated with a RET inhibitor' is based on results from the ongoing study LOXO-RET-17001 (LIBRETTO-001) as of the cut-off date of 15 June 2021. This was an open-label, multicentre, phase 1/2 study which consisted on a dose escalation phase (phase 1) to determine the MTD and RP2D of selpercatinib followed by a Phase 2 expansion with diverse RET-altered cancer cohorts (6 cohorts), among them NSCLC (1L/2L), MTC, and other tumours.

The Phase 1 portion of the study has been completed. The Phase 2 portion is ongoing and continuing to enrol patients with advanced solid tumours.

## Design and conduct of clinical studies

LIBRETTO-001 is non-randomized and non-blinded single arm study. The absence of a control arm is an important limitation and a source of bias for a confirmatory study. Overall, inclusion and exclusion criteria are considered acceptable. Amendments made on eligibility criteria since the initial submission of the CMA (DCO of June 2019) are not expected to have a substantial impact on study population or efficacy data. A new cohort, cohort 6, was introduced by amendment protocol (version 9) to include patients who discontinued another selective RET inhibitor because of intolerance. Efficacy data from patients with MTC in this cohort is not yet available and this was adequately reflected in the therapeutic indication.

The RP2D of selpercatinib (160 mg BID) was selected in Phase 1 and has been used as the starting dose for patients in the Phase 2 of the study. Patients continued selpercatinib dosing in 28-day cycles until PD, unacceptable toxicity, or other reason for treatment discontinuation. Patients with PD could continue selpercatinib if, in the opinion of the investigator, they deriving clinical benefit from continuing study treatment.

The primary efficacy endpoint was ORR based on RECIST v1.1. Given the uncontrolled design of the clinical trial, ORR could be an acceptable primary endpoint. PFS, OS and DOR were assessed as secondary

<div style=\"page-break-after: always\"></div>

endpoints. It is important to consider that even if results in term of ORR are outstanding, interpretation of benefit in term of survival endpoints is difficult and uncertain in uncontrolled setting. FDA censoring rules were used for DoR and PFS. Patients enrolled into the Phase 1 dose escalation as well as the Phase 1 and Phase 2 dose expansion cohorts were grouped to derive the analysis sets. Patients with RETmutant MTC who had received at least 1 dose of selpercatinib and achieved at least 6 months of potential follow-up time from the first dose of selpercatinib (or disease progression or death, whichever occurred first), as of 15 June 2021, were considered eligible for efficacy analyses.

As of the 15 June 2021 data cutoff, 796 patients had been enrolled in the Phase 1 and Phase 2 cohorts and were treated with at least 1 dose of selpercatinib. Of these, 314 patients were RET mutant MTC and are considered eligible for efficacy analyses. Of the 314 efficacy eligible patients with RET-mutant MTC, 221 (70.4%) patients were still on treatment. The most common reason for treatment discontinuation for patients was PD (40 [12.7%]). A total of 21 patients (6.7%) discontinued treatment due to an AE.

Of the 142 MTC:-Cab/-Van patients, 83.1% of patients were still on treatment. The main reason for treatment discontinuation was AE (5.6%) followed by withdrawal of consent (4.2%).

Of the 151 MTC:+Cab/+Van patients, 57.0% of patients were still on treatment. The main reason for treatment discontinuation was progressive disease (23.2%) followed by AE (7.9%).

The MAH provides information on study conduct from Protocol version 8.0 up to Protocol version 9.0 (03 June 2020). Some of the changes introduced with Protocol v8 are the addition of a new cohort (Cohort 6) to allow the inclusion of patients previously treated with another RET-selective inhibitor with around 50 patients planned to be enrolled. Efficacy data from this cohort are not yet available. Moreover, with protocol v9 the number of patients to be enrolled in Cohort 1 and Cohort 5 is increased, in order to accommodate enrolment demand and allow for the characterization of AEs that may occur with low frequency.

A  tabulated  summary  of  important  protocol  deviations  for  RET-Mutant  MTC  safety  population  was provided  The Applicant clarified that none of these deviations were considered to have a marked impact on safety or efficacy evaluations.

The MTC population is relatively young and could be considered representative of the disease as in most of the cases this is a hereditary condition of early onset. The median age for cab and van naïve patients was 57 years old, with patients enrolled from 15 up to 87 years old and the most numerous age group was 45 -64 years. The total population under 18 years old were 2 patients. A total of 47.2% of patients had a baseline ECOG score of 1.

The majority of the MTC:-Cab/-Van patients were stage IV at the diagnosis. Median time from diagnosis to study entry was 54.4 months, which is line with relatively long survival of the disease. At study entry, almost all of the patients were metastatic and present at least one measurable lesion per investigator. Of the 142 MTC: -Cab/-Van patients, 115 patients (81%) were treatment naïve and 27 patients (19%) received  prior  systemic  therapy  including  other  therapies  than  cabozantinib  and/or  vandetanib (chemotherapy, immunotherapy, sorafenib, lenvatinib, radioactive iodine).

Regarding RET mutation, M918T was the most common mutation (60% of patients) although other less frequent mutations were also present (i.e. extracellular cysteine [23.2%], V804M/L [4.2%], and others [12%]). In most cases the method used for RET determination was NGS on tumour (75.4%), followed by PCR (13.4%).

The median time on treatment for the MTC safety population (N=319) was 24.4 months, ranging from 0.2 to 47.8 months. Concerning the dose exposure to selpercatinib, not all the patients reached the intended dose (160 mg BID). Median TOT was 24.4 months in the MTC Safety Population.

<div style=\"page-break-after: always\"></div>

Baseline demographics and disease characteristics for patients previously treated with platinum based chemotherapy remain consistent with those provided at the DCO of June 2019.

## Efficacy data and additional analyses

The evidence supporting of the claimed indication in first line Ret mutant MTC came from the 142 cab/van naïve patients. Of these -cab/-van, 115 patients were naïve to any systemic therapy (MTC:TrtNaive patients); and 27 patients were naïve to Cabozantinib and Vandetanib but previously treated with other systemic therapy (MTC:TrtOther).

Supportive evidence came mostly from the 151 patients previously treated with Cabozantinib and/or Vandetanib.

Cabozantinib and/or Vandetanib naïve mutant MTC: -Cab/-Van patients.

As of the cut-off date of 15 June 2021, the ORR among 142 -Cab/-Van naïve patients was 81.0%; (95% CI:  73.6,  87.1)  by  IRC  and  77.5%  (95%CI:  69.7,  84)  by  Investigator's  assessment.  The  overall concordance rate between IRC and Investigator assessments was 86.6%.

At the time of the DCO, 26 of the 58 responders (44.8%) had progressed or died. The median DOR by IRC assessment was not reached, with a median follow-up of 20.3 months (95% CI: 17.7, 22.1) with 81.7% of responders were still on treatment. The rate of DoR at 12 months was 91.9% (95% CI: 85.0, 95.7); at 24 months, 83.7% (95% CI: 73.0, 90.4).

The clinical benefit rate, defined as proportion of patients with a CR or PR, or SD lasting 16 or more weeks, was 94.4% (134 out of 142 patients; 95% CI: 89.2, 97.5).

The disease control rate, defined as proportion of patients with CR, PR, or SD (of any duration) as their best response, was 96.5% (137 out of 142 patients; 95% CI: 92.0, 98.8).

As determined by IRC assessment, the majority of patients demonstrated a reduction in tumour size from baseline. For the 115 responders in the RET-mutant MTC:-Cab/-Van, the median TTR and TTBR by IRC assessment was 3.5 months and 3.6 months, respectively.

Median PFS by IRC was not reached with a median follow-up of 24.5 months (95% CI: 22.0, 25.2). At the  time  of  data  cutoff,  75.2%  of  patients  were  still  on  treatment  with  no  documented  disease progression. The rate of PFS at 12 months was 91.0% (95% CI: 84.7, 94.8); at 24 months, 81.1% (95% CI: 72.4, 87.3).

Median duration of observed OS was not estimable with 90.1% of patients remaining alive at a median follow-up of 26.3 months (95% CI: 24.3, 27.8). The rate of OS at 12 months was 99.3% (95% CI: 94.9, 99.9), at 24 months was 95.0% (95% CI: 89.0, 97.7), and at 36 months was 89.7% (95% CI: 76.2, 95.8). The OS data is not yet considered mature.

The biochemical response rate for calcitonin was 95.1% (95% CI: 90.1, 98.0) and for CEA was 79.4% (95% CI: 71.6, 85.9).

Analysis  by  subgroups  in MTC:-Cab/-Van patients did not reveal any remarkable difference to main analysis. Overall, ORR were mostly in line with the main analysis.

## Prior +Cab/+Van MTC patients

The ORR in the 151 MTC:+Cab/+Van patients, was of 73.5% (95% CI: 65.7, 80.4) by IRC and 70.9% (95% CI: 62.9, 78.0) by Inv with a concordance rate of 80.1%. There was 14 CR (9.3%).

<div style=\"page-break-after: always\"></div>

The median DoR by IRC assessment was not reached, with a median follow-up of 22.9 months (95% CI: 20.3, 25.4) with 54.1% of patients were still on treatment. The rate of DoR at 12 months was 82.8% (95% CI: 74.1, 88.8); at 24 months, 64.5% (95% CI: 52.9, 73.9). The mDOR by inv was 31.7 months (95%CI: 26.1, NE).

The CBR, was 91.4% (138 out of 151 patients; 95% CI: 85.7, 95.3) per IRC assessment. The ORR of 70.9% for selpercatinib (including 95 patients who did not achieve response on their last prior therapy), was remarkably higher than the ORR of 9.9% (n=15) for the last prior therapy.

The median TTR and TTBR by IRC assessment was 3.5 months and 3.7 months, respectively.

Estimated median duration of PFS by IRC was 34.0 months (95% CI: 25.7, NE) with a median follow-up of 27.6 months (95% CI: 24.929.8). At the time of data cutoff, 45.0% of patients by IRC assessment were still on treatment with no documented disease progression. The rate of PFS at 12 months was 78.7% (95% CI: 70.9, 84.6); at 24 months, 64.4% (95% CI: 55.4, 72.0). Observations based on Investigator assessments were in line with IRC assessments (33.4 months (95% CI: 24.7, NE))

Median OS was not reached with 67.5% of the patients remaining alive and continuing OS follow-up at a median follow-up time of 28.8 months (95% CI: 22.8, 34.5). The rate of OS at 12 months was 87.7% (95% CI: 81.2, 92.1), at 24 months was 77.2% (95% CI: 69.3, 83.4), and at 36 months was 65.5% (95% CI: 53.7, 75.0). The OS data is not yet considered mature.

The biochemical response rate for calcitonin was 91.9% (95% CI: 86.3, 95.7) and for CEA was 74.0% (95%

Overall results were consistent with those of the primary analysis that led to the initial CMA.

The  efficacy  results  among  the  27  patients  who  were  naïve  to  Cabozantinib  and  Vandetanib  but previously treated with other systemic therapy (MTC:TrtOther) are overall consistent with those of naïve to any systemic therapy (MTC:TrtNaive Patients).

## Assessment of paediatric data on clinical efficacy

Selpercatinib is also intended to be used in adolescent patients (i.e. ≥12 years) with RET -mutant MTC. In the study LIBRETTO-001, a total of three adolescent patients (15, 16 and 17 years, respectively) were included. Since according to the PIP (P/0369/2019) at least 2 evaluable subjects must be included for the primary analysis this measure was considered compliant with the PIP. The proposed dose of selpercatinib in adolescent patients with MTC is the same as for adults (i.e. 160 mg BID). However, in the study LOXO-RET-18036, an ongoing study in paediatric patients, including adolescent patients, a dose of 92 mg/m 2  BID (with a maximum dose of 160 mg BID) was considered appropriate. Thus, further justification was requested on the selected dose for adolescent patients with MTC. In study LIBRETTO-001, the same dose was selected for adults and adolescent patients, since from the perspective of drug metabolism, patients 12 years or older can be considered adults. In the case of selpercatinib, it is mainly metabolized by CYP3A4, which by the age of 12 may have reached its adult level of expression. With regard to study LOXO-RET-18036 (LIBRETTO-121), in paediatric patients (6 to 21 years), the planned initial dose (i.e. 92 mg/m2 BID) is intended to result in a similar exposure than the 160 mg/m 2  in adults. The Applicant indicated that any new information, from study LIBRETTO-121 regarding dosing in younger patients will be applied if required.

Of these patients, 2 had a starting dose of 160 mg BID whereas 1 patient had a starting dose of 80 mg BID and escalated to 160 mg BID. Two patients achieved a partial response and 1 had a stable disease lasting longer than 16 weeks. All these 3 patients remain on treatment as of the cut-off date.

<div style=\"page-break-after: always\"></div>

Differences in exposure for extreme body weights do not seem to have a worrying impact in safety based on data provided but the limited number of &lt;50 kg patients included and duration of exposure make it hard to reach any final conclusion about dose adjustment recommendation in these low weight patients.

## Additional efficacy data needed in the context of a conditional MA

The main limitations in relation to the efficacy of selpercatinib are related to the uncontrolled nature of the pivotal evidence which hampers the assessment of the time-to-event endpoints and the limited number of patients included.

To confirm the benefits observed in study LIBRETTO-001 and in order to fulfil a CMA, a global phase 3 study is projected to complete enrolment by August 2023 (LIBRETTO 531 in RET-mutant MTC).

This phase 3 study will be conducted in patients with previously untreated RET -mutant MTC. As of 01 March 2022, the study is approximately 64% enrolled (161 of the planned initial 250 patients).

## 2.4.4. Conclusions on the clinical efficacy

The updated efficacy results from the ongoing phase 1/2 study LIBRETTO-001 in patients previously treated with cabozantinib and/or vandetanib are consistent with those provided in the original submission. For Cab/Van naïve patients (MTC:-Cab/-Van), the obtained ORR of 82% could be considered clinically meaningful. Although immature, K-M estimates for DOR, PFS and OS at several time-points are promising.

Since efficacy results are based on a single clinical trial with immature time-to-event endpoints, data corresponding to a longer follow-up are still required as well as efficacy results from the ongoing phase 3 study LIBRETTO-531 (the SOB study related to the CMA).

The CHMP considers the following measures necessary to address the missing efficacy data in the context of a conditional MA:

- In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET fusion-positive NSCLC, RET fusion -positive thyroid cancer and RET mutant MTC, the MAH should submit the final study report from the pivotal study LIBRETTO-001 by 31 December 2023

- In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET-mutant MTC, the MAH should submit the clinical study report of the Phase 3 study J2G-MC-JZJB (LIBRETTO531) comparing selpercatinib to physician's choice of cabozantinib or vandetanib in patients with progressive, advanced, kinase inhibitor-naive, RET-mutant MTC. The CSR should be submitted by 30 September 2025.

## 2.5. Clinical safety

## Introduction

Safety data are available from a total of 796 patients in the LIBRETTO 001 study which is still ongoing. Of these, 319 (~ 49%) had RET-mutant MTC and includes 142 (44.5%) who were cabozantinib and vandetinib naive. All patients in the ITT population received at least one dose of selpercatinib as of the data cut-off date of 15 June 2021.

<div style=\"page-break-after: always\"></div>

Table 24. Description of Safety Analysis Sets (data Cut-off: 15 June 2021)

| Analysis Set Name         | Analysis Set Description                                                                                                                                             | SAP Name        |   Number of Patients per Analysis Set |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------------------------------|
| Overall Safety Population | All patients who received at least 1 or more doses of selpercatinib regardless of diagnosis or line of therapy                                                       | OSAS            |                                   796 |
| MTC Safety Population     | All patients with RET-mutant MTC who received at least 1 dose of selpercatinib. This is a subset of the Overall Safety Population                                    | MTC total       |                                   319 |
| MTC:-Cab/-Van             | Includes patients with RET-mutant MTC that have had no prior systemic therapy or have been treated with a prior systemic therapy besides cabozantinib and vandetanib | SAS1            |                                   142 |
| MTC:IrtNaive              | Patients naive to any systemic therapy. This analysis set is an ad- hoc subset of MITC:-Cab/-Van                                                                     | SAS1 naive      |                                   115 |
| MTC:IrtOther              | Patients naive to cabozantinib and vandetanib but previously treated with other systemic therapy. This analysis set is an ad-hoc subset of MIC:-Cab/-Van             | SAS1 pretreated |                                    27 |
| MTC:+Cab/+Van             | Includes all patients with RET- mutant MTC previously treated with cabozantinib and/or vandetanib                                                                    | IAS             |                                   156 |

Abbreviations: Cab = cabozantinib; IAS = integrated analysis set; MTC = medullary thyroid cancer; N = number of subjects in the analysis population; NMD = non-measurable disease; OSAS = overall safety analysis set; RET = REarranged during Transfection; SAS = safety analysis set; Tit = treatment; Van = vandetanib.

## Patient exposure

Through 15 June 2021, a total of 796 patients have been treated with selpercatinib at doses ranging from 20 mg QD to 240 mg BID, most patients (96% ) received at least 1 dose of the selpercatinib recommended dose (Phase 2 dose) of 160 mg BID.

Five hundred thirty-nine (539) patients (68%) were still on study, of which 462 patients (58%, including 118 patients with MTC: -Cab/-Van) were still receiving selpercatinib and 77 patients (10%, including 10 patients with MTC: -Cab/-Van) were in follow-up, but off treatment.

The most common reason for treatment discontinuation in the Overall Safety Population was disease progression (23%), followed by AE (8%).

The  most  common  reason  for  treatment  discontinuation  in  the  MTC  Safety  Population  was  disease progression (12, 5%), followed by AE (6.9%).

In the MTC Safety Population, 96.6% patients received at least 1 dose of selpercatinib 160 mg BID and 90% patients had a selpercatinib starting dose of 160 mg.

<div style=\"page-break-after: always\"></div>

Table 25: Treatment and study disposition (MTC Safety Population)

| Status                                                       | Integrated (N=156)   | SAS1 (N=142)   | SASl Naive (N=115)   | SASl Pre-treated (N= 27)   | Total MTC (N=319)   |
|--------------------------------------------------------------|----------------------|----------------|----------------------|----------------------------|---------------------|
| Treatment Status (n, &)                                      |                      |                |                      |                            |                     |
| Discontinued                                                 | 66 42.3)             | 24 (16.9)      | 19 16.5)             | 5 18.5)                    | 94 (29.5)           |
| Continuing                                                   | 90 (57.7)            | 118 ( 83.1)    | 96 (83.5)            | 22 ( 81.5)                 | 225 (70.5)          |
| Reason Treatment Discontinued (n, &)                         |                      |                |                      |                            |                     |
| Progressive Disease                                          | 35(22.4)             | 5 3.5)         | 2 1.7)               | 3 (11.1)                   | 40 ( 12.5)          |
| Adverse Event                                                | 13 8.3)              | 8 5.6)         | 7 6.1)               | 3.7)                       | 22 6.9)             |
| Intercurrent Illness Compromising                            | 1 0.6)               | 0 0.0)         | 0 0.0)               | 0 0.0)                     | 1 0.3)              |
| Ability                                                      |                      |                |                      |                            |                     |
| to Fulfill Protocol Requirements Requirement for Alternative | 2 1.3)               | 0.7)           | 0.9)                 | 0.0)                       | 4（ 1.3)             |
| Treatment                                                    |                      |                |                      |                            |                     |
| Investigator                                                 |                      |                |                      |                            |                     |
| Withdrawal of Consent                                        | 3 1.9)               | 6 4.2)         | 6 5.2)               | 0 0.0)                     | 10 ( 3.1)           |
| Death                                                        | 6 3.8)               | 2 ！ 1.4)       | 1 0.9)               | 1 3.7)                     | 8 2.5)              |
| Other                                                        | 3.8)                 | 2 1.4)         | 2 1.7)               | 0.0)                       | 9( 2.8)             |
| Study Status (n, &)                                          |                      |                |                      |                            |                     |
| Discontinued                                                 | 52(33.3)             | 14 ( 9.9)      | 12 (10.4)            | 2( 7.4)                    | 68 (21.3)           |
| Continuing                                                   | 104 (66.7)           | 128 (90.1)     | 103 ( 89.6)          | 25 (92.6)                  | 251 (78.7)          |
| Reason Study Discontinued (n,&)                              |                      |                |                      |                            |                     |
| Withdrawal of Consent                                        | 9 5.8)               | 6 4.2)         | 6 5.2)               | 0 0.0)                     | 16 ( 5.0)           |
| Lost to Follow-Up                                            | 1 0.6)               | 0 0.0)         | 0 0.0)               | 0 0.0)                     | 1 （ 0.3)            |
| Death                                                        | 39 (25.0)            | 8 5.6)         | 6 5.2)               | 2 7.4)                     | 47 (14.7)           |
| Other                                                        | 3 1.9)               | 0 0.0)         | 0 0.0)               | 0 0.0)                     | 4( 1.3)             |

The median time on treatment was 21.3 and 24.4 months, respectively, for the Overall Safety Population and MTC Safety Population.

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 71.5% in the MTC Safety Population) primarily attributed to adverse events (AEs) (40.8% in the Overall Safety Population and 36.4% in the MTC Safety Population).

## Adverse events

A summary of all-causality and treatment-related AEs registered across data-cut-off dates is shown in below table

<div style=\"page-break-after: always\"></div>

Table 26: Summary of Safety Trends- Overall Safety Population and MTC safety population

|                                                | MTC Safety Pop.     | MTC Safety Pop.     | Overall Safety Pop.   | Overall Safety Pop.   |
|------------------------------------------------|---------------------|---------------------|-----------------------|-----------------------|
| Data cut-off date                              | March 2020 N=315    | Jun 2021 N=319      | March 2020 N=746      | Jun 2021 N=796        |
| Any TEAEs,n (%),[IR]                           | 313 (99.4) [4118.4] | 318 (99.7) [3975.0] | 740 (99.2) [3474.2]   | 795 (99.9) [3581.1]   |
| Related toselpercatinib                        | 293 (93.0) [861.8]  | 304 (95.3) [725.5]  | 690 (92.5) [734.0]    | 756 (95.0) [721.5]    |
| Grade ≥3 TEAEs, n (%), [R]                     | 196 (62.2) [111.5]  | 229 (71.8) [81.3]   | 470 (63.0) [118.5]    | 572 (71.9) [90.8]     |
| Related to selpercatinib                       | 96 (30.5) [35.3]    | 127 (39.8) [28.1]   | 239 (32.0) [39.7]     | 307 (38.6) [31.0]     |
| Serious TEAEs, n (%), [IR]                     | 97 (30.8) [35.1]    | 135 (42.3) [27.7]   | 262 (35.1) [43.4]     | 353 (44.3) [33.7]     |
| Related to selpercatinib                       | 20 (6.3) [5.9]      | 28 (8.8) [4.5]      | 62 (8.3) [8.3]        | 87 (10.9) [6.6]       |
| TEAEs leading to discontinuation,a n (%), [IR] | 15 (4.8) [4.3]      | 23 (7.2) [3.6]      | 45 (6.0) [5.8]        | 64 (8.0) [4.6]        |
| Related to selpercatinib                       | 6 (1.9) [1.7]       | 13 (4.1) [2.0]      | 16(2.1) [2.0]         | 25 (3.1) [1.8]        |
| Fatal TEAEs, n (%) [R]                         | 8 (2.5) [2.3]       | 14 (4.4) [2.2]      | 25 (3.4) [3.2]        | 45 (5.7) [3.2]        |
| Related to selpercatinib                       | 0 (0.0) [0.0]       | 1 (0.3) [0.2]       | 0 (0.0) [0.0]         | 1 (0.1) [0.1]         |

Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; IR = incidence rate; MTC = medullary thyroid cancer, n = number of patients in specific category, N = number of subjects in the analysis population; TEAE = treatment-emergent adverse event.

* Permanently discontinued.

Note: Severity grade assignment based on CTCAE (v4.03).

IR is 100 times the number of patients experiencing the adverse event divided by the event-specific exposure to treatment.

Percentage is calculated based on the number of patients in the column heading as the denominator.

TEAEs are defined as adverse events that start on or after the first administration of selpercatinib

<div style=\"page-break-after: always\"></div>

Summary of Treatment-Emergent Adverse Events-Overall Safety Population and MTC Safety Population

| Analysis Set                            | MTC: -Cab/-Van N=142   | MTC: TrtNaivea N=115   | MTC: TrtOthera N=27   | MTC: +Cab/+Van N=156   | MTC Safety Pop. N=319   | Overall Safety Pop. N=796   |
|-----------------------------------------|------------------------|------------------------|-----------------------|------------------------|-------------------------|-----------------------------|
| Data cut-off date                       | Jun 2021               | Jun 2021               | Jun 2021              | Jun 2021               | Jun 2021                | Jun 2021                    |
| Any TEAEs, n (%)                        | 142 (100.0)            | 115 (100.0)            | 27 (100.0)            | 155 (99.4)             | 318 (99.7)              | 795 (99.9)                  |
| Related to selpercatinib                | 139 (97.9)             | 112 (97.4)             | 27 (100.0)            | 145 (92.9)             | 304 (95.3)              | 756 (95.0)                  |
| Grade ≥3 TEAEs, n (%)                   | 97 (68.3)              | 78 (67.8)              | 19 (70.4)             | 117 (75.0)             | 229 (71.8)              | 572 (71.9)                  |
| Related to selpercatinib                | 64 (45.1)              | 53 (46.1)              | 11 (40.7)             | 55 (35.3)              | 127 (39.8)              | 307 (38.6)                  |
| Serious TEAEs, n (%)                    | 51 (35.9)              | 37 (32.2)              | 14 (51.9)             | 75 (48.1)              | 135 (42.3)              | 353 (44.3)                  |
| Related to selpercatinib                | 16 (11.3)              | 13 (11.3)              | 3 (11.1)              | 11 (7.1)               | 28 (8.8)                | 87 (10.9)                   |
| TEAEs leading to discontinuation, n (%) | 8 (5.6)                | 7 (6.1)                | 1 (3.7)               | 14 (9.0)               | 23 (7.2)                | 64 (8.0)                    |
| Related to selpercatinib                | 6 (4.2)                | 5 (4.3)                | 1 (3.7)               | 7 (4.5)                | 13 (4.1)                | 25 (3.1)                    |
| Fatal TEAEs, n (%)                      | 4 (2.8)                | 3 (2.6)                | 1 (3.7)               | 10 (6.4)               | 14 (4.4)                | 45 (5.7)                    |
| Related to selpercatinib                | 1 (0.7)                | 0 (0.0)                | 1 (3.7)               | 0 (0.0)                | 1 (0.3)                 | 1 (0.1)                     |

Abbreviations: Cab = cabozantinib; MTC = medullary thyroid cancer; N = number of subjects in the analysis population; n = number of patients in the specific category; TEAE = treatment-emergent adverse event; Trt =treatment; Van = vandetanib.

a Subset of MTC:-Cab/-Van population .

The most frequent TEAEs (any grade) occurring in 30% or more in the Overall Safety Population were oedema , diarrhoea, fatigue, dry mouth , hypertension, AST increased, ALT increased, constipation, rash abdominal pain  and nausea .

The most frequent TEAEs (any grade) occurring 30% or more in the MTC Safety Population were oedema , diarrhoea, fatigue , dry mouth , hypertension, AST increased, ALT increased, constipation, rash, nausea, abdominal pain, headache and blood creatinine increased.

The most common Grade ≥ 3 TEAEs in both the Overall and MTC Safety Populations were hypertension followed by ALT increased and AST increased. There were no Grade 5 (fatal) events noted for these 3 TEAEs in either of the populations.

The most common treatment-emergent serious adverse events (TESAEs) occurring in ≥2% of patients in both the Overall and MTC Safety Populations was pneumonia.

## Serious adverse event/deaths/other significant events

## Serious AEs

The most common serious TEAEs observed in both the Overall Safety Population and MTC:-Cab/Van are shown in table below

<div style=\"page-break-after: always\"></div>

|                                       | MTC:-Cab/-Van N=142   | MTC:-Cab/-Van N=142   | Overall SafetyPopulation N=796   | Overall SafetyPopulation N=796   |
|---------------------------------------|-----------------------|-----------------------|----------------------------------|----------------------------------|
| Preferred Term?                       | All Causality n (%)   | Related n (%)         | All Causality n (%)              | Related n (%)                    |
| Datacut-offdate                       | Jun 2021              | Jun 2021              | Jun 2021                         | Jun 2021                         |
| Patients with treatment-emergent SAEs | 51 (35.9)             | 16 (11.3)             | 353 (44.3)                       | 87 (10.9)                        |
| Pneumonia                             | 6 (4.2)               | 0 (0.0)               | 33 (4.1)                         | 0 (0.0)                          |
| Pleural effusion                      | 1 (0.7)               | 1 (0.7)               | 24 (3.0)                         | 5 (0.6)                          |
| Abdominal pain                        | 4 (2.8)               | 1 (0.7)               | 20 (2.5)                         | 3 (0.4)                          |
| Dyspnoea                              | 0 (0.0)               | 0 (0.0)               | 18 (2.3)                         | 0 (0.0)                          |
| Hyponatraemia                         | 1 (0.7)               | 0 (0.0)               | 18 (2.3)                         | 0 (0.0)                          |
| Diarhoea                              | 3 (2.1)               | 1 (0.7)               | 15 (1.9)                         | 3 (0.4)                          |
| Sepsis                                | 0 (0.0)               | 0 (0.0)               | 13 (1.6)                         | 0 (0.0)                          |

Abbreviations: Cab = cabozantinib; MedDRA = Medical Dictionary for Regulatory Activities; MTC = medullary thyroid cancer; N = number of subjects in the analysis population, n = number of patients in the specific category, SAE = serious adverse event; TEAE = treatment-emergent adverse event; Van = vandetanib.

* Adverse events were coded using MedDRA (version 21.0).

Note: Percentage is calculated based on the number of patients in the column heading as the denominator.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in &gt;2% of patients in the MTC (-Cab/-Van) Safety Populations were pneumonia, abdominal pain and diarrhoea.

The most common treatment-emergent serious adverse events (TE-SAEs) occurring in &gt;2% of patients in both the Overall and MTC Safety Populations were pneumonia, abdominal pain.

## Deaths

Table 27: Summary of deaths Overall Safety Population

|                             | RET-mutant MTC (N=319) n (8)   | RET Fusion- positive Thyroid (N= 54) n(名)   | RET Fusion- positive NSCLC (N=356) n (%)   | Overall Safety (N=796) n (%)   |
|-----------------------------|--------------------------------|---------------------------------------------|--------------------------------------------|--------------------------------|
| Within28 Days of Last Dose  | 14（ 4.4)                       | 1.9)                                        | 33( 9.3)                                   | 56( 7.0)                       |
| Disease Progression         | 2（ 0.6)                        | 1 1.9)                                      | 15 （ 4.2)                                  | 19 2.4)                        |
| Adverse Event               | 11（ 3.4)                       | 0 0.0)                                      | 17 ( 4.8)                                  | 34( 4.3)                       |
| Other                       | 1(0.3)                         | 0 0.0)                                      | 1( 0.3)                                    | 0.4)                           |
| Morethan28DaysafterLastDose | 33(10.3)                       | 7 13.0)                                     | 78(21.9)                                   | 137(17.2)                      |
| Disease Progression         | 27 8.5)                        | 5 9.3)                                      | 58 (16.3)                                  | 109 (13.7)                     |
| Adverse Event               | 3 0.9)                         | 1 1.9)                                      | 6( 1.7)                                    | 10 (1.3)                       |
| Other                       | 3 0.9)                         | 1 1.9)                                      | 14( 3.9)                                   | 18 (2.3)                       |

was disease progression.

<div style=\"page-break-after: always\"></div>

Table 28: Summary of deaths Overall Safety Population and MTC (-Cab/-Van) Patients

|                                              | MTC:-Cab/-Van N=142   | Overall Safety Population N=796   |
|----------------------------------------------|-----------------------|-----------------------------------|
| Data cut-off date                            | Jun 2021              | Jun 2021                          |
| Within 28 days of the last dose, n (%)       | 3 (2.1)               | 56 (7.0)                          |
| Disease progression                          | 0 (0.0)               | 19 (2.4)                          |
| Adverseevent                                 | 3 (2.1)               | 34 (4.3)                          |
| Other                                        | 0 (0.0)               | 3 (0.4)                           |
| More than 28 days after the last dose, n (%) | 5 (3.5)               | 137 (17.2)                        |
| Disease progression                          | 2 (1.4)               | 109 (13.7)                        |
| Adverse event                                | 1 (0.7)               | 10 (1.3)                          |
| Other                                        | 2 (1.4)a              | 18 (2.3)                          |

Abbreviations: Cab = cabozantinib; MTC = medullary thyroid cancer; N = number of patients; n = number of patients in the specific category; Van = vandetanib.

* Other included: (1) umknown - patient stayed on treatment for 3.5 months, and death occurred 2.5 years after the last dose of selpercatinib, and (2) patient admitted to hospital with abdominal pain and blood in stool.

Note: Percentage is calculated based on the number of patients in the column heading as the denominator.

## Adverse Events of Special Interest

## AST/ALT increased

AST and ALT increases were reported in 36.7% and 35.7% of patients in the Overall Safety Population and 35.1% and 32.3% of patients in the MTC Safety Population, respectively. Majority were of Grade 1 or 2

## Hypertension

The incidence of any-grade hypertension was reported in similar proportion in both the Overall Safety Population (41%) and MTC safety population (44.8%), 20% and 22% were Grade ≥ 3 in the Overall and MTC Safety Population, respectively. Patients with a documented history of hypertension displayed a higher incidence of treatment-emergent Grade 3 hypertension than patients without (28% versus 14%, respectively). This trend is the same in the MTC safety population (30.9% versus 15.3, respectively).

## Hypersensitivity

The overall incidence of any-grade hypersensitivity was 5.9% in the Overall Safety Population. A total of 15 patients (1.9%) in the Overall Safety and 3 patients (0.9%) in the MTC Safety Population had Grade 3 hypersensitivity

## QT prolongation

Electrocardiogram QT prolonged was reported as a TEAE in similar proportion of the patients in both the Overall  (21.1%) and MTC (22.9%) Safety Populations. Most patients had TEAEs of Grade 1 or 2 in severity in both the Overall Safety (16.3%) and MTC safety (18.8%) population.

## Laboratory findings

The highest incidence of any grade treatment-emergent laboratory abnormality across haematology parameters was reported for decreased lymphocyte count (51.8% and 48.6%) and decreased white blood cell count (48.7% and 41.8%) in both the Overall Safety Population and the MTC Safety Population, respectively.

<div style=\"page-break-after: always\"></div>

The highest incidence of any grade treatment-emergent serum abnormality was reported for calcium decreased (58.7 and 66.4 %), and albumin decreased (55.7% and 53.3%) in both the Overall Safety Population and the MTC Safety Population, respectively.

## Safety in special populations

There were no significant differences in the incidence of TEAEs among the age, sex, and race subgroups in the Overall Safety and MTC Safety Populations.

## Discontinuation due to adverse events

The most frequently reported TEAEs leading to doses being withheld in 5% or more patients in both the Overall  Safety  Population  and  Treatment-Naïve  Patients  (MTC:-Cab/-Van)  were  ALT  increase,  AST increased, diarrhoea, and hypertension.

The most frequently reported TEAEs leading to a dose reduction in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients (MTC:-Cab/-Van) were ALT and AST increase.

The most frequently reported TEAEs leading to permanent discontinuation of selpercatinib in 4 or more patients in the Overall Safety Population were ALT increased, fatigue, AST increase, and sepsis. All other AEs occurred in less than 4 patients. In Treatment-Naïve Patients (MTC:-Cab/-Van) no events leading to permanent discontinuation of selpercatinib were reported in more than 1 patient.

## Post marketing experience

As of November 2021, Selpercatinib was approved in 36 countries including those in the EU, the US and Switzerland for treatment of patients with RET fusion-positive NSCLC, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. Specific patient populations and dosing guidance vary by country.  Cumulatively,  up  to  the  08  November  2021,  an  estimated  1000  patients  were  exposed  to selpercatinib worldwide. The data reported from the post marketing setting, is generally consistent with the  known  safety  profile  of  selpercatinib.  Most  events  were  reported  as  non-serious  and  the  most frequently reported events were recognised ADRs for selpercatinib or clinically expected in the target indication.  Overall,  no  new  significant  safety  information  has  been  identified  from  post  marketing sources. The periodic safety update report/periodic benefit-risk evaluation report with a data lock of 08 November 2021 confirmed and supported the previously established favourable benefit-risk profile for selpercatinib in the currently approved indications.

## 2.5.1. Discussion on clinical safety

Safety  was  evaluated  in  patients  in  the  Overall  Safety  Population  (N=796)  and  in  the  MTC  Safety Population (N=319) who received at least 1 dose of selpercatinib as of the data cut-off date of 15 June 2021.

In terms of exposure, the median time on treatment was 21.29 and 24.4 months, respectively, for the Overall Safety Population and MTC Safety Population. In the Treatment-Naïve Population (n=142), the median treatment duration is 25.3 months (range: 0.2 to 44.4 months) and 83.8% of patients were on treatment for at least 24 months.

The median relative dose intensity was similar for the Overall Safety Population (94.6%) and the MTC Safety Population (95.0%).

<div style=\"page-break-after: always\"></div>

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 71.5% in the MTC Safety Population) primarily attributed to adverse events (AEs) (40.8% in the Overall Safety Population and 36.4% in the MTC Safety Population).

The types and incidence rates of AEs leading to doses being withheld, dose reductions, and treatment discontinuation were consistent between the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van).

The most frequent TEAEs occurring in 30% or more patients in both the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were oedema, and dry mouth.

The most frequent Grade ≥ 3 TEAEs reported in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were hypertension , followed by ALT increased and AST increased .

The most frequent TESAEs reported in 2% or more patients both in the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were pneumonia and abdominal pain.

Fatal TEAEs were reported in 21 patients at the initial MAA compared with 45 patients at the 15 June 2021 data cut-off. In Treatment-Naïve Patients, a fatal (Grade 5) TEAE was experienced by a total of 8 patients (5.6%), including 3 patients who died of AE within 28 days of the last dose of selpercatinib. None in the MTC Safety Population were reported by the investigator as treatment-related.

The adverse events of special interest (AESIs) analysed did not change compared to those reported previously.

The safety profile observed in the data from the 15 June 2021 cut-off remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile  is  consistent  between  the  Treatment-Naïve  Patients  (MTC  -Cab/-Van)  and  the  Overall  Safety Population.

## Additional safety data needed in the context of a conditional MA

Additional safety data including comparative data will be provided as part of the studies imposed as specific obligations. Longer follow-up from LIBRETTO-001 will allow a better characterisation of the longterm safety and the randomised phase 3 study LIBRETTO-531 will allow a contextualisation of the safety data compared to the control arm.

## 2.5.2. Conclusions on clinical safety

The overall safety profile of selpercatinib in Treatment-Naïve Patients (MTC -Cab/-Van) is consistent with that of the Overall Safety Population. The updated results provided in this analysis show the safety profile of selpercatinib is consistent with that reported previously, even with longer duration of treatment.

The CHMP considers the following measures necessary to address the missing safety data in the context of a conditional MA:

- In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET fusion-positive NSCLC, RET fusion -positive thyroid cancer and RET mutant MTC, the MAH should submit the final study report from the pivotal study LIBRETTO-001 by 31 December 2023

- In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET-mutant MTC, the MAH should submit the clinical study report of the Phase 3 study J2G-MC-JZJB (LIBRETTO-531) compar ing selpercatinib to physician's choice of cabozantinib or vandetanib in patients

<div style=\"page-break-after: always\"></div>

with progressive, advanced, kinase inhibitor-naive, RET-mutant MTC. The CSR should be submitted by 30 September 2025.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 2.1 with the following content:

## Safety concerns

Table 29: Summary of Safety Concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                             |
|------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                   |
| Important potential risks    | Liver injury Cardiac arrhythmia due to QT prolongation Reproductive and developmental toxicities                       |
| Missing information          | Exposure and safety in patients with severe hepatic impairment Exposure and safety in patients with cardiac impairment |

## Pharmacovigilance plan

Routine pharmacovigilance activities are considered sufficient to characterise the risks of the product.

## Risk minimisation measures

## Table Part V.2. Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern   | Risk Minimisation Measures                                     | Pharmacovigilance Activities                                                                         |
|------------------|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Liver injury     | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                 | Risk Minimisation Measures                                                                                                                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                                                         |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                | Additional risk minimisation measures: Not Applicable                                                                                                                                                                                                                                    | Additional pharmacovigilance activities: Studies: None                                                                                                                               |
| Cardiac arrhythmia due to QT prolongation                      | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4. Additional risk minimisation measures: Not Applicable                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Studies: None                          |
| Reproductive and developmental toxicity                        | Routine risk minimisation measures: SmPC Section 4.6 Additional risk minimisation measures: Not Applicable                                                                                                                                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • Pregnancy and Breastfeeding follow-up forms Additional pharmacovigilance activities: |
| Exposure and safety in patients with severe hepatic impairment | Routine risk minimisation measures: A clinical pharmacology study assessing the effect of hepatic impairment on the pharmacokinetics of selpercatinib is completed. SmPC is updated based on the safety and pharmacokinetics data. Additional risk minimisation measures: Not Applicable | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study: None                              |
| Exposure and safety in patients with cardiac impairment        | Routine risk minimisation measures: None                                                                                                                                                                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:                                                                                        |

<div style=\"page-break-after: always\"></div>

| Safety Concern   | Risk Minimisation Measures                            | Pharmacovigilance Activities                              |
|------------------|-------------------------------------------------------|-----------------------------------------------------------|
|                  | Additional risk minimisation measures: Not Applicable | None Additional pharmacovigilance activities: Study: None |

Routine risk minimisation measures are sufficient to minimise the risks of the product in the proposed indications.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The proposed revisions do not significantly affect the overall readability. It is not considered necessary to conduct consultation with target patient groups further to that performed for the initial MAA.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The MAH is seeking an extension of indication  for Retsevmo (selpercatinib) as monotherapy  for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) not previously treated with a RET inhibitor.

## 3.1.2. Available therapies and unmet medical need

No selective agents are approved specifically for patients with RET-mutant MTC as a first-line therapy; after first-line therapy, selpercatinib is the only selective RET inhibitor approved in the EU.

The  unselective  MKIs  vandetanib  and  cabozantinib  are  approved  for  the  treatment  of  patients  with unresectable locally advanced or metastatic MTCs, in adults and including children over the age of 5 in the case of vandetanib, irrespective of the RET status and irrespective of prior treatment.

<div style=\"page-break-after: always\"></div>

Table 30: Response and Survival Rates of Current Standard of Care in MTC

<!-- image -->

| Therapeutic        | Vandetanib                          | Vandetanib     | Cabozantinib                       | Cabozantinib         |
|--------------------|-------------------------------------|----------------|------------------------------------|----------------------|
| Population         | MTC (irrespective of RET mutation)a | RET-mutantMTCa | MTC (irespective of RET mutation)b | RET-mutantMTCc       |
| N on study drug    | 231                                 | 110            | 219                                | 169                  |
| ORR,%              | 45                                  | 51.8           | 28                                 | 32                   |
| PFS (months)       | PFS (months)                        | PFS (months)   | PFS (months)                       | PFS (months)         |
| Median HR (95% CI) | NRd 0.46 (0.31, 0.69)               |                | 11.2 0.28 (0.19, 0.40)             | 15 0.23 (0.14, 0.38) |

Abbreviations: CI = confidence interval; HR = hazard ratio; MTC = medullary thyroid cancer; N = number of subjects in the analysis population; NR = not reached; ORR = objective response rate; PFS = progression-free survival; RET = REarranged during Transfection.

- a ZETA (Wells et al. 2012).
- b EXAM (Elisei et al. 2013).
- C EXAM (Sherman et al. 2016).
- d Estimated using Weibull model to be 30.5 months.

## 3.1.3. Main clinical studies

Clinical  safety  and  efficacy  of  selpercatinib  in  treatment-naive  patients  with  advanced  RET-mutant medullary thyroid cancer (MTC) are based on analyses of interim data from LIBRETTO-001 (LOXO-RET17001).

LIBRETTO-001 is a global, multi-cohort, open-label, phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. The phase 2 portion evaluates efficacy in cohorts based on tumour type, type of RET alteration, and prior treatment. The primary objective was to determine ORR by IRC assessment according to RECIST 1.1. DOR, PFS and OS were secondary endpoints.

## 3.2. Favourable effects

At the data cut-off 15 June 2021, 142 MTC:-Cab/-Van patients were efficacy evaluable and the ORR was 81.0% (95% CI: 73.6, 87.1) by IRC and 77.5% (95% CI: 69.7, 84.0) by investigator assessment. 22 patients (15.5%) exhibited a confirmed CR and 93 patients (65.5%) experienced PR.

The median TTR was 3.45 months by IRC and 3.53 by investigator. The rate of DoR at 12 months was 91.9% (95% CI: 85.0, 95.7); at 24 months, 83.7% (95% CI: 73.0, 90.4). Median DoR was not reached with a median follow-up of 20.3 months (95% CI: 17.7, 22.1) by IRC and 21.2 months (95% CI: 17.5, 23.1) by investigator.

The median PFS (IRC) was not reached, with 17% events observed and median follow-up of 24.5 months (95% CI: 22.0, 25.2). The rate of PFS at 12 months was 91.0% (95% CI: 84.7, 94.8), at 24 months 81.1% (95% CI: 72.4, 87.3).

Median OS was not reached at the time of the DCO (5.6% of events observed). The rate of OS at 12 months was 99.3% (95% CI: 94.9, 99.9), at 24 months was 95.0% (95% CI: 89.0, 97.7), and at 36 months was 89.7% (95% CI: 76.2, 95.8). Efficacy of selpercatinib seems consistent across most important subgroups.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

The uncertainties and limitations are mainly related to the uncontrolled nature of the pivotal trial which hampers the interpretation of the time-to-event endpoints (PFS, OS).

Even though updated efficacy data have been provided for RET mutant MTC patients regardless of line therapy, the median DOR, OS and PFS continued to be not estimable. The KM estimates for time-toevent endpoints (PFS, OS) seem promising, but they remain immature.

These limitations will be addressed post authorisation with the submission of updated data and longer follow-up from the LIBRETTO-001 study and the conduct of LIBRETTO-531, a randomised phase III trial in patients with progressive, advanced, kinase inhibitor-naive, RET-mutant MTC.

## 3.4. Unfavourable effects

Safety data are available from a total of 796 patients in the LIBRETTO-001 study.

Safety  was  evaluated  in  patients  in  the  Overall  Safety  Population  (N=796)  and  in  the  MTC  Safety Population (N=319) who received at least 1 dose of selpercatinib as of the data cut-off date of 15 June 2021.

In terms of exposure, the median time on treatment was 21.29 and 24.4 months, respectively, for the Overall Safety Population and MTC Safety Population. In the Treatment-Naïve Population (n=142), the median treatment duration is 25.3 months (range: 0.2 to 44.4 months) and 83.8% of patients were on treatment for at least 24 months.

The median relative dose intensity was similar for the Overall Safety Population (94.6%) and the MTC Safety Population (95.0%).

The most reported dose modification was dose withheld (72.9% in the Overall Safety Population and 71.5% in the MTC Safety Population) primarily attributed to adverse events (AEs) (40.8% in the Overall Safety Population and 36.4% in the MTC Safety Population).

The types and incidence rates of AEs leading to doses being withheld, dose reductions, and treatment discontinuation were consistent between the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van).

The most frequent TEAEs occurring in 30% or more patients in both the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were oedema, and dry mouth.

The most frequent Grade ≥ 3 TEAEs reported in 5% or more patients in both the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were hypertension, followed by ALT increased and AST increased.

The most frequent TESAEs reported in 2% or more patients both in the Overall Safety Population and Treatment-Naïve Patients (MTC -Cab/-Van) were pneumonia and abdominal pain.

Fatal TEAEs were reported in 21 patients at the initial MAA compared with 45 patients at the 15 June 2021 data cut-off. In Treatment-Naïve Patients, a fatal (Grade 5) TEAE was experienced by a total of 8 patients (5.6%), including 3 patients who died of AE within 28 days of the last dose of selpercatinib. None in the MTC Safety Population were reported by the investigator as treatment-related.

The adverse events of special interest (AESIs) analysed did not change compared to those reported previously.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

Data on long-term safety is lacking and will be provided post approval with updated data from LIBRETTO-001 and the randomised phase 3 study LIBRETTO-531. Effects Table

Table 31: Effects Table for Retsevmo in RET-mutant medullary thyroid cancer (data cut-off: 15 June 2021)

<!-- image -->

| Effect                                                    | Short descript ion                            | Unit                                          | Treatment                                                                                    | Con trol                                      | Uncertainties / Strength of evidence          | References                                    |
|-----------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Favourable Effects                                        | Favourable Effects                            | Favourable Effects                            | Favourable Effects                                                                           | Favourable Effects                            | Favourable Effects                            | Favourable Effects                            |
| Treatment-Naïve Patients (-Cab/-Van) (n= 142)             | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142)                                                | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) |
| ORR                                                       | rate                                          | n% (95% CI)                                   | 115 (81.0) (73.6, 87.1)                                                                      | NA                                            | uncontrolled data                             | LIBRETTO-001                                  |
| DOR                                                       | median                                        | Months (95% CI)                               | NR (NE, NE)                                                                                  | NA                                            | Immature and uncontrolled data                | LIBRETTO-001                                  |
| PFS                                                       | median                                        | Months (95% CI)                               | NE (NE, NE)                                                                                  | NA                                            | Immature and uncontrolled data                | LIBRETTO-001                                  |
| OS                                                        | OS landmark rates                             | (%) (95% CI)                                  | 99.3 (94.9, 99.9) at 12 months 95.0 (89.0, 97.7) at 24 months 89.7 (76.2, 95.8) at 36 months | NA                                            | Immature and uncontrolled data                | LIBRETTO-001                                  |
| Unfavourable Effects                                      | Unfavourable Effects                          | Unfavourable Effects                          | Unfavourable Effects                                                                         | Unfavourable Effects                          | Unfavourable Effects                          | Unfavourable Effects                          |
| Treatment-Naïve Patients (-Cab/-Van) (n= 142)             | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142)                                                | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) | Treatment-Naïve Patients (-Cab/-Van) (n= 142) |
| Any TEAEs                                                 | rate                                          | n (%)                                         | 142 (100)                                                                                    | NA                                            | uncontrolled data                             |                                               |
| selpercatinib Grade ≥3 TEAEs                              | rate                                          | n (%)                                         | 97 (68.3) 64 (45.1)                                                                          | NA                                            | uncontrolled data                             |                                               |
| selpercatinib TEAEs leading to treatment discontinuati on | rate                                          | n (%)                                         | 8 (5.6) 6 (4.2)                                                                              | NA                                            | uncontrolled data                             |                                               |
| Related to selpercatinib                                  | Related to selpercatinib                      | Related to selpercatinib                      | Related to selpercatinib                                                                     | Related to selpercatinib                      | Related to selpercatinib                      | Related to selpercatinib                      |
| Serious TEAEs                                             | rate                                          | n (%)                                         | 51 (35.9)                                                                                    | NA                                            | uncontrolled data                             |                                               |
| selpercatinib Fatal TEAEs                                 | rate                                          | n (%)                                         | 4 (2.8)                                                                                      | NA                                            | uncontrolled data                             |                                               |
| Related to selpercatinib                                  |                                               |                                               | 1 (0.7)                                                                                      |                                               |                                               |                                               |

Abbreviations:  ORR: Objective Response Rate, DOR: Duration of Response, PFS: Progression Free Survival, OS:

Overall Survival

<div style=\"page-break-after: always\"></div>

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

Data supporting this application are based on one single-arm trial (LIBRETTO-001), which make interpretation of time to event endpoints and any potential long-term benefit challenging. Nevertheless, this approach is acceptable in the context of a CMA for a product intended for a population with an unmet medical need as long as the effect observed in ORR is outstanding and durable.

For cabozantinib and/or vandetanib naïve patients, clinical data from a larger and more mature dataset of patients are available (median follow-up time of 21 months). The obtained ORR of 81% is considered meaningful in patients with RET-mutant MTC in first-line setting. Median DOR was not reached at a median follow-up time of 20.27 months and K-M estimates at landmark time points for PFS and OS allow to anticipate lasting benefits from treatment. The ORR benefit for the intended population was observed with selpercatinib regardless of the line of therapy.

Although, other approved front-line therapies with established benefit exist, efficacy with selpercatinib is considered compelling. Indirect comparisons of available results (KM estimates of PFS and OS) with selpercatinib against those reported with MKIs cabozantinib and vandetinib seem promising and give some support to the benefit of the treatment in the first line. The ORRs for selpercatinib are higher than those reported for cabozantinib and vandetinib. Although PFS and OS data are not yet mature, the median follow-up of 24.54 and 26.25 months, respectively, provide robust data of the 24 months PFS and OS landmark rates. The 24-month PFS landmark rate (with a PFS rate of 81.1% [95% CI: 72.4, 87.3]) exceeds median PFS for the cabozantinib study. The median follow-up time has not yet exceeded the estimated 30.5 months median PFS in the vandetinib study; however, the PFS rate for selpercatinib at 30 months was 79.7% (95% CI: 70.6, 86.3).

The safety profile observed in the data from the 15 June 2021 cut-off remains consistent with previously reported data. No new ADRs or AESIs have been identified since initial authorisation and the safety profile is consistent between the Treatment-Naïve Patients and the Overall Safety Population.

## 3.6.2. Balance of benefits and risks

The provided results from LIBRETTO-001 have shown efficacy in term of tumour shrinkage. Responses seem durable and independent of treatment line. However, given the remaining uncertainties mostly related to the uncontrolled design of the pivotal study, comparative data from the phase 3 study (LIBRETTO-531 or J2G-MC-JZJB) together with further follow-up data from the pivotal trial LIBRETTO001 are required as confirmatory evidence (SOBs).

## 3.6.3. Additional considerations on the benefit-risk balance

As comprehensive data on the product are also not available in the first-line treatment of RET mutant MTC, a conditional marketing authorisation was requested by the applicant for this extension of indication. The new indication for this product falls within the scope of Article 14-a of Regulation (EC) No 726/2004 concerning conditional marketing authorisations, as it aims at the treatment of a lifethreatening disease.

Furthermore, the CHMP considers that the product fulfils the requirements for a conditional marketing authorisation:

<div style=\"page-break-after: always\"></div>

- The benefit-risk balance is positive, as discussed above.
- It is likely that the applicant will be able to provide comprehensive data. The applicant will provide confirmatory data from the ongoing LIBRETTO-531 study, an open-label randomised phase 3 study comparing selpercatinib to physician's choice of cabozantinib or vandetanib in patients with progressive, advanced, kinase inhibitor-naive, RET-mutant MTC (J2G-MC-JZJB). This study is currently recruiting and the submission of the final clinical study report (CSR) is expected by 30 September 2025. As of 01 March 2022, the study is approximately 64% enrolled (161 of the planned initial 250 patients) with approximately 60% of patients coming from EU countries. An extension of indication to include the first-line treatment of patients with MTC is not expected to have an impact on study recruitment. Results of the LIBRETTO-531 study are intended to provide a comprehensive data package and potentially convert the conditional MA into a full MA. There are currently supply constraints related to sourcing of vandetanib (Caprelsa) in the EU due to limited stock availability from the MAH. At this time, there has been no impact to patient treatment, nor is it anticipated that treatment will be impacted (even though amendments to the CTA have been submitted to mitigate any potential impact).
- Unmet medical need will be addressed, as selpercatinib is a selective treatment showing a response rate of such a magnitude that a clinical benefit would be expected compared to first line available unselective MKI options, vandetanib and cabozantinib. A major therapeutic advantage over existing therapies can therefore be concluded. In addition, selpercatinib has a differential safety profile compared to existing therapies with a significantly lower rate of TEAEs leading to permanent treatment discontinuation.
- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Given the positive benefit/risk and the unmet medical need in the applied indication as described above, this is considered fulfilled.

## 3.7. Conclusions

The overall B/R of Retsevmo for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) not previously treated with a RET inhibitor is positive subject to the specific obligations and conditions imposed in order to obtain further clinical data to generate a comprehensive clinical data set and inform the long-term efficacy and safety profile of the product in this new indication.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

<div style=\"page-break-after: always\"></div>

| C.I.z   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | Type IB   | None   |
|---------|--------------------------------------------------------------------------------------------------|-----------|--------|

Extension of indication to include first-line treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents 12 years and older based on interim results from Study LIBRETTO-001 (LOXO-RET-17001) on the clinical safety and efficacy of selpercatinib in patients with RET-mutant MTC who are cabozantinib and vandetanib treatment-naïve (MTC:-Cab/-Van). LIBRETTO001 is a global, multicohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours.  As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.  Version 3.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection. The application also includes an updated Phase II Environmental Risk Assessment in order to reflect the patient population as per the approved indication.

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annexes I, IIIB and to the Risk Management Plan are recommended.

There are no new conditions but this recommendation is subject to the following specific obligations in Annex II:

| Description                                                                                                                                                                                                                                                                                                                                                                                                        | Due date         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| - In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET fusion-positive NSCLC, RET fusion -positive thyroid cancer and RET mutant MTC, the MAH should submit the final study report from the pivotal study LIBRETTO-001 by                                                                                                                                    | 31 December 2023 |
| In order to further confirm the efficacy and safety of selpercatinib in the treatment of patients with RET-mutant MTC, the MAH should submit the clinical study report of the Phase 3 study J2G-MC-JZJB (LIBRETTO- 531) comparing selpercatinib to physician's choice of cabozantinib or vandetanib in patients with progressive, advanced, kinase inhibitor-naive, RET-mutant MTC. The CSR should be submitted by | 28 February 2025 |

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Retsevmo is not similar to Cometriq within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers, that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 2).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this group of variations. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

<div style=\"page-break-after: always\"></div>

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Retsevmo-II/0014/G

## Attachments

1. SmPC Package Leaflet (changes highlighted), as a relevant example with changes highlighted as adopted by the CHMP on 21 July 2022.

## Appendices

1. CHMP AR on similarity dated 21 July 2022
2. CHMP AR on the significant clinical benefit in comparison with existing therapies dated 21 July 2022

<div style=\"page-break-after: always\"></div>

- 1.

CHMP group of variations including an extension of indication assessment report